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ABSTRACT OF DISSERTATION

BUILDING TOOLS FOR IMPROVED MODULATION OF THE HUMAN GABAA
RECEPTOR, A CENTRAL NERVOUS SYSTEM TARGET FOR THE TREATMENT
OF ANXIETY
In the U.S., anxiety is recognized as an increasing range of mentally and physically
debilitating psychiatric health disorders with significant economic repercussions. Over the
last 20 years, several novel anti-anxiety therapies have entered the drug development
pipeline, but none have made it to market.
The work in this dissertation focused on structurally modifying valerenic acid (VA), a
structurally unique carboxylated sesquiterpene acid found in Valeriana officinalis. VA
is putatively reported to have allosteric modulatory activity of the human GABAA
receptor, a ligand-gated ion channel responsible for attenuating neurotransmissions.
Structural modeling of VA’s GABAA receptor interaction suggests that constraining the
isobutenyl group relative to the 5,6 membered ring system of VA could improve its
binding specificity and affinity to the GABAA receptor. In planta, valerena-1,10-diene
(VLD) is synthesized from farnesyl pyrophosphate (FPP) valerenadiene synthase
(VDS), a sesquiterpene synthase. VLD is then carboxylated at one of its isobutenyl
terminal methyl groups to yield VA. Our first objective was to engineer the VDS
enzyme for altered product specificity and a more chemically constrained VLD scaffold.
Using computational homology modelling and phylogenetic sequence analysis of
characterized sesquiterpene synthases, amino acid residues in or near the active site and
potentially impinging on catalytic specificity of VDS were identified.
Residues were mutated via site-directed mutagenesis and mutants evaluated in vivo
and in vitro. While wild type VDS’ products were 66 % VLD, 5 % alloaromadendrene, and 29 % bicyclogermacrene (BCG), mutant Y535F yielded solely
BCG. VDS with alanine or serine substituted for asparagine at position 455 lost all its
ability to produce any of the wild type products and instead yielded a suite of seven new

products dominated by germacrene-D-ol (≥ 40 %).
To install a carboxylic acid functional group onto the sesquiterpene hydrocarbon
scaffolds, we focused on the development of a host platform harboring an
endomembrane system suitable for the expression of eukaryotic cytochrome P450
enzymes (P450s). As an example, plasmid co-expression of VDS, Lactuca sativa
germacrene-A oxidase, and Artemisia annua cytochrome P450 oxidoreductase yielded
an average 2mg/L of VA.
For biological evaluation of sesquiterpene analogs, HEK293 cells transiently transfected
with the human GABAA receptor subunit genes ⍺1, β3, and 𝛾𝛾2L, as well as a HEK293 cell
line stably expressing the same GABA subunit genes, were optimized for sensing changes
in membrane potential using a fluorescent bioassay. Effective concentration of test
compounds and absolute magnitude of membrane depolarization in the transiently
transfected cells gave the greatest responsiveness as determined for 𝛾𝛾-aminobutyric acid
(EC50 = 808 ± 206 nM, Emax = 13,309 ± 953 AFU’s), clonazepam (EC50 = 15 ± 8 nM,
Emax = 4,211 ± 334 AFU’s), and VA (EC50 = 2,397 ± 341 nM, Emax = 5,935 ± 104
AFU’s). Abscisic acid, gibberellic acid, and cyclopartheniol demonstrated little to no
detectable activity for modulating the human GABAA receptor.
KEYWORDS: anxiety, terpene synthase engineering, yeast engineering, fluorescent
bioassay, GABAA receptor allosteric modulators
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CHAPTER 1. INTRODUCTION
1.1

Prevalence and economic burden of anxiety psychiatric disorders in the US
Excessively worrying about (or perceiving there is) an imminent threat with no

evidence to suggest it is harmful, results in an emotional state of enhanced vigilance and
hyperarousal (Russell, 1980) concomitantly accompanied by physiological changes, such
as increases in sweating, dizziness, and heart rate, clinically summarizes the debilitating
psychiatric mental health disorder classified as anxiety (Calhoon & Tye, 2015; Davis et al.,
2010; Robinson et al., 2019; Shackman & Fox, 2016). Succinctly, anxiety is clinically
characterized as a subjective emotional mental state originating from unfounded worrying
about past or current events which can lead to physical disruption of the neurochemical
equilibrium within the limbic system, resulting in irrational social behavior(s) (Calhoon &
Tye, 2015; Robinson et al., 2019). In the US, anxiety disorders (AD), codified into seven
subtypes under the DSM-V (American Psychiatric, 2013) (Table 1.1), burden
approximately 32% of the US adult population (18yrs. & older) over the course of his and
her lifetime (Kessler et al., 2012). Each AD subtype’s etiology and disorder pathogenesis
framed the chosen specifiers for the proper psychiatric diagnosis (Kupfer, 2015). Out of
the seven AD subtypes, Kessler et al. (Kessler et al., 2012) found social anxiety (social
phobia) and specific phobias were the most prevalent AD subtypes among US adults, with
a lifetime prevalence of 13% and 13.8%, respectively. Separation anxiety disorder (SAD)
generalized anxiety disorder (GAD), panic attack disorder (PD), and agoraphobia were the
least prevalent among the US adult population, with lifetime prevalence’s estimated at
6.6%, 6.2%, 5.2%, and 2.6%, respectively. It should be noted, Kessler et al.’s report

1

(Kessler et al., 2012) preceded the release of fifth edition of the DSM, which was the first
edition to include selective mutism (SM) as an AD subtype.
Beyond the classification as the most prevalent mental health disorder in the US to
date (Cryan & Sweeney, 2011; Garakani et al., 2020), treating AD incurs substantial cost
to both the healthcare system and the patient, placing significant strain on a nation’s
potential economic growth (Greenberg et al., 1999; Shirneshan, 2013; Wittchen et al.,
2011). For example, from 2009 to 2010 the total estimated direct costs (i.e., the consumed
medical and non-medical resources) for treating AD in the US was estimated at $1657.57
per person, or $33.7 billion in 2013 US dollars (Shirneshan, 2013). This is equivalent to
24% of all 2013 US healthcare expenditures and 0.2% of the US’ 2013 GDP 1 (Konnopka
& König, 2020). AD is a debilitating, costly psychiatric condition that will only continue
to burden the US’ healthcare system preventing future economic growth. One way to
remedy the AD societal burden may be to increase the volume of FDA-approved drugs
specifically designed to target novel anxiolytic pathways with the overall goal of equivalent
or greater efficacy, lower abuse potential, and a reduced number of adverse effects.

1

Gross Domestic Product

2

Table 1.1 The Seven Subtypes of Anxiety Disorders Recognized by the DSM-V
Anxiety Disorder Subtypes

Brief Description

Generalized Anxiety Disorder (GAD)

Excessive anxiety and worry (apprehensive expectation),
occurring more days than not for at least 6 months, about a
number of events or activities (such as work or school
performance)

Panic Attack Disorder (PD)

An abrupt surge of intense fear or intense discomfort that reaches
a peak within minutes.

Separation Anxiety Disorder (SAD)

Developmentally inappropriate and excessive fear or anxiety
concerning separation from those to whom the individual is
attached.

Social Anxiety Disorder

Marked fear or anxiety about one or more social situations in
which the individual is exposed to possible scrutiny by others.

Specific Phobia (SP)

Marked fear or anxiety about a specific object or situation.

Agoraphobia

A marked fear or anxiety about two (or more) of the following
five situations: using public transportation, being in open spaces,
being in enclosed spaces, standing in line or being in a crowd, or
being outside the home alone.

Selective Mutism (SM)

Continual failure to speak in specific settings (e.g., school, social
situations) despite speaking normally in others (e.g., at home).

3

1.2

Psychotherapies for the treatment of AD
Psychotherapies, which encompasses cognitive behavioral therapy (CBT)

(Bandelow et al., 2015) and transcranial magnetic stimulation (TMS) (Zhang et al., 2019),
offer AD patients a clinically supported alternative to or a supplemental treatment option
with pharmaceutical-based AD approved treatments. Though vitally important to the AD
treatment regimen, the rest of this section will be spent focused on the pharmacological
anxiolytic advances made to help those struggling daily with anxiety. For a more in-depth
understanding of CBT and TMS methodology, the reader is encouraged to view
(Kaczkurkin & Foa, 2015) and (Lefaucheur et al., 2014), respectively.

1.3

Pharmacotherapies for the treatment of AD
As of August 2021, there were 17 drugs (Table 1.2) currently still Food & Drug

Administration (FDA)-approved for treatment of AD recognized under the DSM-V (Table
1.1), including obsessive compulsive disorder (OCD) and post-traumatic stress disorder
(PTSD) (American Psychiatric, 2013). OCD and PTSD were removed from the list of AD
subtypes and placed into their own separate categories with the release of the fifth edition
of the DSM in 2013. Currently, the anti-depressant drug class remains the first line of
treatment for chronic AD, more specifically- the selective serotonin re-uptake inhibitors
(SSRIs) (Table 1.2, drug #’s 8-12,) (Garakani et al., 2020; Sartori & Singewald, 2019).
SSRI’s increase the synaptic serotonin concentration via blocking the 5-HT1 re-uptake
transporter, resulting in the migration of feelings and emotions associated with AD (Griebel
& Holmes, 2013). Though documented as safe and highly efficacious (compared with the

4

placebo in RCTs 2 (Jakubovski et al., 2019)), SSRI’s are known to have undesirable adverse
effects such as, weight gain, sexual dysfunction, and insomnia (Ferguson, 2001). For acute
AD treatment (typically less than a month), the benzodiazepine (BZD) drug class (drug #’s
1-6, Table 1.2) remains highly favored among clinicians, given this drug class has a clinical
history of rapidly (within minutes) mitigating symptoms of AD via reduction in excitatory
action

potentials

in

the postsynaptic neuron

through

GABAergic inhibitory

neurotransmission within the CNS dating back to 1963 with the FDA approval of diazepam
(Valium®) for GAD (Olfson et al., 2015; Sartori & Singewald, 2019). Greater details on
BZDs’ mechanism of action are detailed below. Although efficacious, the benzodiazepines
have an alarming risk of physical dependence and addictive properties among young adults
(Cryan & Sweeney, 2011; Licata & Rowlett, 2008; Tauseef, 2012) and were reported to
cause anterograde amnesia within geriatric populations (Mejo, 1992).

2

Randomized Clinical Trial
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Table 1.2 List of Current FDA-Approved Drugs for Treating AD
Number

Generic (Brand) Name

Drug Class

FDA Approval Year

AD Approval Subtype

1.

Alprazolam (Xanax)

BZD

1981

GAD, PD

2.

Clonazepam (Klonopin)

BZD

1975

GAD

3.

Chlorazepate (Tranxene)

BZD

1972

GAD

4.

Diazepam (Valium)

BZD

1963

GAD

5.

Lorazepam (Ativan)

BZD

1977

GAD

6.

Oxazepam (Serax)

BZD

1965

GAD

7.

Clomipramine (Anafranil)

TCA

1989

OCD

8.

Escitalopram (Lexapro)

SSRI

2003

GAD

9.

Fluoxetine (Prozac)

SSRI

1995

OCD, PD

10.

Fluvoxamine (Luvox)

SSRI

1997

OCD, SAD

11.

Paroxetine (Paxil)

SSRI

1996

OCDb, PD, SAD,PTSDb ,GAD

12.

Sertraline (Zoloft)

SSRI

1996

OCDb, PD, PTSDb, SAD

13.

Venlafaxine (Effexor XR)

SNRI

1999

GAD, SAD, PD

14.

Duloxetine (Cymbalta)

SNRI

2007

GAD

15.

Buspirone (Buspar)

Otherc

1986

GAD

16.

Meprobamate (Miltown)

Otherd

1955

GAD

17.

Trifluoperazine (Stelazine)

APY

2001

GAD
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1.4

BZDs mechanism of action
For anxiety disorders, it is clinically documented that excessive or in-appropriate

worry can be rapidly mitigated by enhancing the GABAergic inhibitory neurotransmission
with use of BZD class of drugs (#’s 1-6, Table 1.2) (Low et al., 2000; Rudolph &
Knoflach, 2011). In the mid 1950’s, the first benzodiazepine, chlordiazepoxide, was
synthesized by Sternbach at the Hoffman La Roche Pharmaceutical Company (Cryan &
Sweeney, 2011). This drug class, formed from the fusion of a benzene and a diazepine ring,
binds to a set of specific amino acid residues located at the interface of an α and γ subunit,
which induces a conformation shift within the receptor, resulting in an increase in the
affinity for γ-aminobutyric acid (GABA), its natural agonist. Concomitantly, increasing the
frequency at which the chloride ion-selective channel is in the open vs. closed state (Figure
1.1).

7

Figure 1.1 The human GABAA receptor is a vitally important ligand-gated ion channel
responsible for inhibitory neurotransmission in the central nervous system. The chloride
ion (blue circles) selective channel opens after a GABA molecule (green circle) binds to
one of its two binding sites (at interface of the 𝛼𝛼 & 𝛽𝛽 subunits) (Kim et al., 2020; Masiulis
et al., 2019). BZDs allosterically modulate the GABAA receptor, via binding to the BZ site
(orange square) resulting in an increase in the receptor’s affinity for GABA. Khom and
company (Benke et al., 2009; Khom et al., 2007; Khom et al., 2016; Khom et al., 2010)
demonstrated valerenic acid acts as a positive allosteric modulator after binding to the 𝛽𝛽2,3
subunits (red square) below 30 µM and as direct activator above, observed within in vitro
electrophysiology models. Figure was adapted from Jacob et. al. (Jacob et al., 2008).

8

1.5

Mechanism of GABAA receptor activation
In the mammalian brain, there must be a balance between excitatory and inhibitory

neurotransmission for the brain to function properly (i.e., cortical rhythmic activity)
(Bannai et al., 2015). Most of the inhibitory transmission is carried out via the GABAergic
synapses, which releases gamma amino-butyric acid (GABA) into the synaptic cleft where
it binds to presynaptic neurons inhibiting the release of excitatory neurotransmitters, such
as glutamate. In concert, up to two molecules GABA will bind to postsynaptic GABAA
receptors, inducing a confirmational shift, moving the receptor from a “closed” to an
“open” state (Figure 1.1). In the “open” state, negative chloride ions move freely from the
presynaptic cleft down the ion-selective channel into cytosol of the target neuron down
their electrochemical gradient. The rapid influx of chloride ions hyperpolarizes the cell,
moving the resting membrane potential (typically -80mV for a neuron) in the negative
direction reducing the likelihood of an excitatory action potential in the neighboring postsynaptic neuron (Mohler et al., 2005; Tauseef, 2012; Tretter et al., 2008). Structurally,
GABA receptors are pentameric ligand-gated ion channels comprised of two α and two β
subunits with a variable subunit of either γ, ε, π, θ, or δ in a pseudosymmetric orientation
(Jacob et al., 2008; Kim et al., 2020; Masiulis et al., 2019). The α2 subunit containing
GABAA receptors (preferentially expressed in the hippocampus, striatum, and the olfactory
bulb) are responsible for anxiolysis and preferentially targeted by the barbiturate,
benzodiazepine, ethanol, and neurosteroid drug classes (Engin et al., 2012). Hence, play a
vital role in the fields of anesthesia and acute anxiolytic treatment (Althaus et al., 2020;
Jurd et al., 2003; Pritchett et al., 1988).
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1.6

The future of anxiolytic drug discovery
Since 2007, the FDA has granted approval designation for only two anxiety disorder

pharmacotherapies: duloxetine (Cymbalta®) for the treatment of GAD and fluvoxamine
maleate (Luvox®) for the treatment of OCD. To date, there have been no approvals of New
Drug Applications (NDAs) with the FDA specifically designated for the treatment of AD,
despite the long list of ongoing FDA-approved clinical trials (Garakani et al., 2020; Sartori
& Singewald, 2019). One plausible reason for the recent reduced output of AD approved
drugs is the common perception that the they are efficacious (Table 1.2), though the
literature supports a different perspective (Garakani et al., 2020). Dr. Bystritsky
(Bystritsky, 2006) reported only 60-85% AD patients respond (experience at least a 50%
improvement) to the current psycho and pharmacological US approved AD treatments,
hence exploration of alternative AD treatments with greater efficacy, limited adverse
effects, and reduced abuse liabilities are warranted. The latest pre-clinical and clinical
efforts in AD treatments have looked to target novel receptors in the CNS putatively linked
to the anxiety neural circuitry (Sartori & Singewald, 2019), such as the N-methyl-Daspartate (NMDA) (Sterpenich et al., 2019), cannabinoid type 1 (CB) (Christine & Phan,
2014), and vasopressin type 1A (V1A) (Lee et al., 2013) receptors. Interestingly, nicotine,
a psychostimulant, was evaluated as an anxiolytic remedy; however, it exhibited
paradoxical anxiolytic and anxiogenic pharmacodynamic properties in pre-clinical animal
models (Picciotto et al., 2002). Currently, ketamine (NMDA receptor antagonist) and
cannabis (complex mixture of chemistries with known agonistic activity for the CB
receptor) are under phase 2/3 clinical trials for their anxiolytic activities.
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1.7

Use of valerian for its anxiolytic properties
For millennia, civilizations have exploited the diverse, biologically active chemistry

within plants to provide for their medicinal needs (Barrett et al., 1999; Cragg & Newman,
2013; Dias et al., 2012). Our earliest records indicate, the Mesopotamians (ca. 2600 B.C.)
extracted oils from Cupressus sempervirens and Commiphora species to treat ailments such
as the common cough, cold, and infections (Cragg & Newman, 2013; Dias et al., 2012). In
Greece 2nd century A.D., Galen, a physician and pharmacist, prescribed valerian, a crude
extract from the roots of Valeriana officinalis to patients suffering from insomnia.
Intriguingly, valerian was later re-purposed as an anxiolytic agent to treat shell shock
syndrome during WWII in England (Bent et al., 2006; Houghton, 1988, 1999; Ricigliano
et al., 2016). Due to its unique anxiolytic properties, valerian’s biological chemistry has
been under investigation since the 1950’s. To date, scientists have discovered that valerenic
acid (VA), a carboxylated sesquiterpenoid produced within the roots of V. officinalis, binds
to specific amino acid residues on the GABAA receptor 𝛽𝛽 2,3 subunits (Figure 1.1) (Benke
et al., 2009; Khom et al., 2007; Khom et al., 2016; Khom et al., 2010). VA binding induces

a conformational change within the GABAA receptor leading to a post-synaptic inhibition
of the target neuron, which by itself has been noted to incite anxiolytic effects in vitro and
in vivo (Benke et al., 2009; Houghton, 1988; Khom et al., 2007; Khom et al., 2016; Kopp
et al., 2010; Luger et al., 2015; Murphy et al., 2010). In vitro, VA has bifurcating
mechanisms of actions at the GABAA receptor. It acts as an allosteric modulator below 30
𝜇𝜇M and as a direct activator above the 30 𝜇𝜇M threshold. These are comparable to the
benzodiazepine and barbiturate drug classes, respectively. Previous in silico work by Luger

et. al. (Luger et al., 2015), positied VA’s flexibile isobutenyl side chain forms a network
of hydrophobic and van der Waals interactions with several amino acid residues within a
11

specific region of the 𝛽𝛽 2,3 subunits. Khom and company (Khom et al., 2016) tested several

VA analogs for improved potentcy and selectivity, however; none of the analogs physically
constrained VA’s “floppy” isobutenyl side chain. Physically constraining VA’s isobutenyl
side chain by such measures as cyclization would potentially lower its entropic barrier to
reaching its active confirmation within the GABAA receptors. Such hypotheses are
supported by the literature (Allen et al., 2016; Pan et al., 2013).
Hence, the following body of work explores various strategies for the biosynthesis
of novel constrained VA analogs within a yeast host system. The immediately following
chapter dives into the rational, directed evolution of VDS towards more constrained
hydrocarbon precursors (CHAPTER 2). Afterwards, CHAPTER 3 lays out the initial
blueprint for enhancing the titers of carboxylated sesquiterpenoids within an
endomembrane yeast host platform. Then, CHAPTER 4 concludes the work with the
outline of an optimized in vitro biological screening assay for detecting novel chemistries
which directly modulate recombinantly expressed human GABAA receptors. A summary
chapter concludes this entire body of work reflects on the experimental paths undertaken
by the author and those which were left explored (CHAPTER 5). It is the opinion of this
author that these unexplored experimental paths should be considered for continuation of
synthesizing and testing novel chemistries with enhanced modulation activity of the
GABAA receptor with the end downstream goal of greater potency, reduced abuse
potentials and minimized adverse effects.
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CHAPTER 2. STRUCTURALLY GUIDED REPROGRAMMING OF
VALERENADIENE SYNTHASE
2.1

Introduction
Terpenes and terpenoids arise from the condensation of ubiquitous 5 carbon

isoprenoid building blocks isopentyl pyrophosphate and dimethylallyl pyrophosphate into
linear precursors that undergo complex regio- and stereochemical cyclization reactions
catalyzed by terpene synthases, TPSs. The elegance of these cyclized terpenes is most
easily captured by noting the multiple ring systems, multiple stereocenters and variety of
substituent groups captured in small molecules of 500 Daltons or less (Christianson, 2017;
Poulter & Rilling, 1978; Ruzicka, 1953; Tantillo, 2011). Estimates for the number of
naturally occurring terpenes identified to date exceeds 100,000, but this only accounts for
1 to 10% of the theoretical possibilities (Christianson, 2017; Poulter & Rilling, 1978;
Ruzicka, 1953; Tantillo, 2011). To achieve such chemodiversity, TPSs begin with the
generation of a highly reactive carbocation intermediate species through the ionization of
their allylic diphosphate substrate (Figure 2.1). Then, through a series of well-defined
intramolecular bond formations; stereospecific hydride, methyl, and methylene migrations;
and various ring openings/closings, TPSs form penultimate terpene/terpenoid scaffolds.
The catalytic cascade is finally halted and the hydrocarbon product released from the active
site when the reactive carbocation intermediate is either quenched by the capture of a water
molecule within the active site or supplied by the bulk solvent (generating hydroxylated
terpene species (Grundy et al., 2016)), a stereospecific proton is abstracted to form a double
bond (Felicetti & Cane, 2004), or by a nucleophilic addition (alkylation) from a side chain
of an amino acid within the active site (Kersten et al., 2015). Interestingly, TPSs utilize one
or various combinations of these reaction mechanisms to produce some of the worlds most

renowned therapeutics, agrochemicals, fragrances, and nutraceuticals (Singh & Sharma,
2015).
From a biotechnological point of view, to access the diversity of terpenoid scaffolds
(Paddon et al., 2013) it is imperative to gain a fundamental comprehension of the primary
catalytic cascades the TPS uses to cyclize the ionized isoprenoid substrate into highlydesired terpene product(s) (Christianson, 2017). This can be achieved through structurefunction mapping of key amino acid residues responsible for the catalytic plasticity found
within the TPS (Abdallah et al., 2018; Dixit et al., 2017; Greenhagen et al., 2006; Salmon
et al., 2015; Schrepfer et al., 2016; Yoshikuni, Ferrin, et al., 2006). Previously, the Ro and
Chappell groups independently characterized valerena-1,10-diene synthase (VDS) from
Valeriana officinalis (Pyle et al., 2012; Yeo et al., 2013). VDS is a class I sesquiterpene
synthase which converts the acyclic, all trans farnesyl diphosphate (FPP) into a 5- and 6fused member ring system with an unusual isobutenyl substituent group known as
valerena-1,10-diene (VLD). Therapeutically, valerenic acid (VA), VLD’s carboxylated
derivative arising from the action of a cytochrome P450(s) localized to the roots of V.
officinalis (Bos et al., 1996; Ricigliano et al., 2016), was shown to allosterically modulate
the mammalian GABAA receptor in vitro and mitigate the physical signs of stress in murine
animal models (Benke et al., 2009; Khom et al., 2007; Khom et al., 2010). In silico models
predict VA’s flexible isobutenyl acidic tail forms hydrophobic interactions with specific
amino acid residues within the ß2 & 3 subunits of the GABAA receptor (Luger et al., 2015).
While the Khom group had moderate successes in generating valerenic acid analogs with
improved selectivity and potency for the 𝛽𝛽 -subunit in vitro, none of these analogs

physically constrained the flexible isobutenyl side chain (Khom et al., 2016). The literature
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supports the theory that if one constrains a ligand (ex. a drug), one lowers the entropic
barrier of reaching its “active” binding conformation, naturally enhancing its ability to bind
to its target receptor (Allen et al., 2016; Pan et al., 2013). One such way of introducing
conformational constraint is through the stabilization of the ligand’s side chains via
cyclization which, by default, reduces the ligand’s number of rotatable bonds (Allen et al.,
2016). Hence, the aim of the current work was to identify key amino acids within VDS
which mapped to reaction products that offered structural constraint at VLD’s isobutenyl
side chain (Figure 2.1). Using the information and experimental strategies from previous
efforts to alter TPS specificity (Bell et al., 2014; Greenhagen et al., 2006), we discovered
amino acid substitutions that altered the product specificity towards native, structurally
constrained terpene reaction products or completely derailed the catalytic trajectory
towards abortive, structurally constrained reaction products not previously identified for
VDS.
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Figure 2.1 Valerena-1,10-diene (17) is the predominate reaction product of the wild type
VDS and can arise from two possible routes, initiated by either a 1,10 (germacrenyl route,
red arrows and highlighting) or a 1,11 (humulyl route, blue arrows and highlighting) ring
closure of 1 (Paknikar et al., 2013; Pyle et al., 2012; Yeo et al., 2013). The other major
products 9 and 10, generated by the wild type VDS, could arise from a germacrenyl cation
route as suggested previously (Stefan Garms et al., 2010; Vattekkatte et al., 2017). An
earlier study also used specifically labeled FPP to suggest the biosynthetic origin of ⍺gurjunene (12) via a germacrenyl route (Schmidt et al., 1999). Mutant VDS enzymes lose
their ability to biosynthesize the dominant products (9, 10, and 17), and instead generated
a diverse set of sesquiterpenes: germacrene D (8) - (germacrenyl cation route) (Picaud et
al., 2006); ⍺-humulene (5) and β-caryophyllene (11) - (humulyl cation route) (Cai et al.,
2002); ⍺-copaene (14), 𝛿𝛿-cadinene (15), and cubebol (16) - possibly arising from a
helmintogermacrenyl carbocation (green arrows and highlighting) (6) (Stefan Garms et al.,
2010). ΔCCR, the cyclopropylcarbinylcation-cyclopropylcarbinylcation rearrangement
(Poulter & Rilling, 1978) was suggested by Paknikar et. al. (Paknikar et al., 2013). Details
of the ϕPaths-a,-b, &-c are provide in Yeo et. al. (Yeo et al., 2013).
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2.2

Materials and Methods

2.2.1

Molecular Modeling

Homology modeling of enzymes were carried out with MODELLER v9.21
(University of California, San Francisco, CA) (Sali & Blundell, 1993) using the Nicotiana
tabacum (tobacco) 5-epi-aristolochene synthase (EAS) coordinates (Protein Data Bank
entry 5EAT) (Starks et al., 1997) as the template. Model was evaluated for accuracy with
the freely available SaliLab Model Evaluation v2.1 program (Eramian et al., 2008; Melo
et al., 2002; Shen & Sali, 2006). The model with the smallest predicted root-mean-squared
deviation and DOPE score was subsequently used for docking studies. Proposed reaction
intermediates were constructed in CHEMDRAW (PerkinElmer) and were energyminimized using MOPAC2016 (Stewart Computational Chemistry, Colorado Springs)
(Stewart, 2016). Proposed reaction intermediates were docked into the VDS model using
Autodock Vina v1.1.2 (The Scripps Research Institute, La Jolla, CA) (Trott & Olson,
2010). Images were made using PYMOL v1.8 (Delano Scientific, South San Francisco,
CA) (Schrodinger, 2015).

2.2.2

Site-directed mutagenesis of VDS

Site-directed mutagenesis was carried out using a modified version of the
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) according to the
manufacturer’s instructions. In brief, PrimeSTAR® HS DNA Polymerase (Takara) was
used in a “round-the-horn” in vitro PCR mutagenesis reaction (98° C for 2 min, 55° C for
17

15 s, 72° C for 7 min for 18 cycles; 72° C for 7 min final extension for 1 cycle). DpnI
digestion of template plasmid and transformation into E. coli DH5α competent cells were
carried out per the manufacturer’s protocols. All mutations were verified by single-pass
DNA sequencing (UK HealthCare Genomics Laboratory). The template construct for all
site-directed mutagenesis reactions was pET-28a(+)-VDS (NCBI Accession #AGB05610)
as described previously (Yeo et al., 2013). Mutagenic primers are listed in Table 2.1.
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Table 2.1 VDS mutagenic primers, with mutated codon colored in red and underlined
Mutation
I307L
T310A
T310I
T310M
T310S
S311A
S311I
S311F
S311T
C415A
C415S
C452A
N455A
N455C
N455S
N455T
M531L
M531V
Y535F

Direction
FWD
REV
FWD
REV
FWD
REV

5' -Sequence- 3'
TCTCGTGCAAGAAAGATGTTTGTCAAAGTACTTAATTTGACATCT
ATGTGTCGTCTATGAGAGATGTCAAATTAAGTACTTTGACAAACA
AGAAAGATGTTTGTCAAAGTAATTAATTTGGCATCTCTCATAGAC
GTCATATGTGTCGTCTATGAGAGATGCCAAATTAATTACTTTGAC
AGAAAGATGTTTGTCAAAGTAATTAATTTGATATCTCTCATAGAC
GTCATATGTGTCGTCTATGAGAGATATCAAATTAATTACTTTGAC

FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV

AGAAAGATGTTTGTCAAAGTAATTAATTTGATGTCTCTCATAGAC
GTCATATGTGTCGTCTATGAGAGACATCAAATTAATTACTTTGAC
AGAAAGATGTTTGTCAAAGTAATTAATTTGTCATCTCTCATAGAC
GTCATATGTGTCGTCTATGAGAGATGACAAATTAATTACTTTGAC
AAGATGTTTGTCAAAGTAATTAATTTGACAGCTCTCATAGACGAC
CATACGAGTCATATGTGTCGTCTATGAGAGCTGTCAAATTAATTA
AAGATGTTTGTCAAAGTAATTAATTTGACAATTCTCATAGACGAC
CATACGAGTCATATGTGTCGTCTATGAGAATTGTCAAATTAATTA
AAGATGTTTGTCAAAGTAATTAATTTGACATCTCTCATAGACGAC
CATACGAGTCATATGTGTCGTCTATGAGAGATGTCAAATTAATTA
AAGATGTTTGTCAAAGTAATTAATTTGACAACTCTCATAGACGAC
CATACGAGTCATATGTGTCGTCTATGAGAGTTGTCAAATTAATTA

FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV

ACGAGTATCTTAAAGTTGCATTGATATCAGCTGGTTATATGTTAC
AATGAAATAGTTGAGAGTAACATATAACCAGCTGATATCAATGCA
ACGAGTATCTTAAAGTTGCATTGATATCATCTGGTTATATGTTAC
AATGAAATAGTTGAGAGTAACATATAACCAGATGATATCAATGCA
ACGAATAACCCTTTGATTCTTATAGCCTCGGCTACTATCAATAGA
ACCTTATCATCCGCGAGTCTATTGATAGTAGCCGAGGCTATAAGA
CCTTTGATTCTTATAGCCTCGTGTACTATCGCTAGACTCGCGGAT
CCAACCTTATCATCCGCGAGTCTAGCGATAGTACACGAGGCTATA
CCTTTGATTCTTATAGCCTCGTGTACTATCTGTAGACTCGCGGAT
CCAACCTTATCATCCGCGAGTCTACAGATAGTACACGAGGCTATA
CCTTTGATTCTTATAGCCTCGTGTACTATCTCTAGACTCGCGGAT
CCAACCTTATCATCCGCGAGTCTAGAGATAGTACACGAGGCTATA

FWD
REV
FWD
REV
FWD
REV
FWD
REV

CCTTTGATTCTTATAGCCTCGTGTACTATCACTAGACTCGCGGAT
CCAACCTTATCATCCGCGAGTCTAGTGATAGTACACGAGGCTATA
GCGGCCTCTTTATTTGGCATGCTTTTTGAATGTATTCTACAAAGA
ACCAATCTTCATCTTTGTAGAATACATTCAAAAAGCATGCCAAAT
GCGGCCTCTTTATTTGGCATGCTTTGTGAATGTATTCTACAAAGA
ACCAATCTTCATCTTTGTAGAATACATTCACAAAGCATGCCAAAT
CCTCTTTATTTGGCATGCTTTATGAATGTATTCTTCAAAGATGAA
TTAGAGTGTGTGTACCAATCTTCATCTTTGAAGAATACATTCATA
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2.2.3

In vivo product analysis

Reaction products of mutant proteins were profiled via heterologous expression in
BL21 (DE3) cells. Plasmids harboring the correct coding sequence for mutant enzymes
were co-transformed into E. coli BL21(DE3) with pBbA5c-MevT(CO)-MBIS(CO,ispA)
(obtained from Addgene, plasmid #35151) (Peralta-Yahya et al., 2011). Recombinant
bacterial colonies were selected with kanamycin (25 µg/mL) and chloramphenicol (17.5
µg/mL) and 3 independent colonies from each plate were inoculated into 1 mL of 2xYT +
2 % glycerol liquid media with antibiotics and incubated at 37° C for 16-20 h with shaking.
The next morning, cells from overnight seed culture were diluted into 10 mL of 2xYT + 2
% glycerol liquid media at an OD600 = 0.05 supplemented with antibiotics and overlaid
with 10 % n-dodecane. Shake flask fermentations were incubated at 37° C for 2 h before
cooling the flasks at 4° C for 10 min. After addition of IPTG (Isopropyl β-D-1thiogalactopyranoside) to 0.4 mM, the flasks were incubated at 28° C for an additional 20
h. The cultures were then centrifuged at 920g for 10 min and the dodecane overlay removed
for GC-MS analysis. To ensure sufficient extraction (>80 %) of the total hydrophobic
enzymatic products, optimization studies were conducted prior to this work in which a
known concentration of hexadecane (a non-native enzymatic product) was spiked into the
bacterial culture to measure the extraction efficiency with the dodecane overlay.
Aliquots of the dodecane overlay were analyzed on an Agilent 7890 GC (1:9 split
injection; HP-5MS column, 30 m x 0.25 mm, 0.25 μm film, 250° C inlet temperature; oven
temperature was 100° C initially, ramped to 140° C (10° C/min), then to 200° C (5° C/min),
and finally increased to 300° C (120° C/min) and held for 5 min; 0.9 mL/min He flow rate)
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connected to a 5975C Agilent Technologies mass spectrometer (run in positive ionization
mode, 70 eV, scanning 40-500 amu). Sesquiterpene products were identified by
comparison of mass spectra to authentic standards, matches to the NIST v2.0 library, and
those reported by Yeo et. al. (Yeo et al., 2013) (Figure 2.2, Figure 2.3). The classified
sesquiterpene products, whose peak areas were greater than or equal to 1 % of the total
sesquiterpene peak areas, were quantified against known concentrations of βcaryophyllene, a bicyclic ring constrained sesquiterpene (Cai et al., 2002). The results from
the detected and quantified sesquiterpene products are summarized in Table 2.2 & Table
2.3.

21

Figure 2.2 EI-Mass spectra of sesquiterpenes detected from in vivo expression in E. coli
BL21(DE3) cells of wildtype and mutant VDS enzymes.
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Figure 2.3 (Figure 2.2 (con’t)) EI-Mass spectra of sesquiterpenes detected from in vivo
expression in E. coli BL21(DE3) cells of wildtype and mutant VDS enzymes.
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2.2.4

In vitro mutant expression for enzyme assays

Plasmids harboring wild type or mutant genes coding for VDS were expressed in
BL21(DE3) cells as described above. Overnight, saturated cultures were inoculated into
2xYT + 2 % glycerol liquid media containing kanamycin (25 µg/mL) at an OD600 equal to
0.05 and grown at 37º C until an OD600 of 0.5 to 1.0. The cultures were then induced with
400 mM IPTG and incubated at 23° C for 20 h before collecting the cells at 6,000g for 10
min. The cell pellets were stored at -80º C until processed.
Cell pellets were lysed in 50 mM NaH2PO4, pH 7.4, 300 mM NaCl, 5 mM imidazole,
and 5 % glycerol (v/v)) by sonification (30 % power, 5 bursts, 20 s each, 1 min rest in
between) using a QSonica® 500 equipped with a 1.6 mm probe. The cell debris was
removed by centrifugation at 21,000g for 30 min at 4° C. Total protein concentrations were
estimated by the Bradford assay (Bio-Rad) using bovine serum albumin as the standard.

2.2.5

Steady-State Kinetic determinations

Michaelis-Menten kinetics were determined for each mutant enzyme and compared
with wildtype using radiolabeled [1-3H] FPP (20 Ci mmol-1, American Radiolabeled
Chemicals) under similar assay conditions as detailed in Yeo et. al. (Yeo et al., 2013).
Briefly, 10 µL (1-3 µg/µL crude protein) of the cleared lysate was incubated with 1-60 µM
[1-3H] FPP in a 50 µL total reaction volume for a 15 min reaction time at 37° C. Reactions
were stopped with 50 µL of 2x Stop Buffer (0.4 M NaOH, 0.2 M EDTA) and the 3H-labeled
hydrocarbon products extracted with 200 µL n-hexanes. After a silica scrub of the hexane
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extract to remove unreacted prenyl diphosphates and prenyl alcohols (Bell et al., 2014),
aliquots were counted in a liquid scintillation counter. A crude lysate from bacteria
transformed with the empty pET28(a)+ vector (Novagen) was used for background
subtraction. Michaelis-Menten kinetic analysis was performed using GraphPad enzyme
kinetic software v9 (San Diego, CA). Kinetic assays were performed in technical triplicate
from a single transformed bacterial colony.

2.2.6

In Vitro Product Analysis

For GC-MS profiling of wildtype and mutant enzymes, reactions were carried out as
previously described by Yeo et. al. (Yeo et al., 2013), with a few modifications. Aliquots
of the cleared bacterial lysate (1-3 µg/µL total crude protein) were incubated with 230 µM
cold FPP in 250 mM Tris-HCL, pH 7.0, 50 mM MgCl2 (1 mL total reaction volume),
overlaid with 1 mL n-hexanes at 37° C in 4 mL glass vials. After 16 h, 600 µL aliquots of
the organic overlay were carefully dried down under a gentle nitrogen stream while kept
on ice. Concentrated samples were resuspended in n-hexanes and small volumes injected
onto the GC-MS for profiling as described above.

2.2.7

Immunodetection of VDS Enzymes

Expression levels of wildtype and mutant enzymes were determined by separating
aliquots of soluble cleared E. coli lysates by SDS-PAGE under reducing conditions, as
previously detailed in Bell et. al. (Bell et al., 2014). Proteins were transferred to a
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nitrocellulose membrane, blocked with 5 % non-fat dry milk, and probed with a mouse
monoclonal anti-polyHistidine antibody conjugated to alkaline phosphatase (Sigma
Aldrich, Cat# A5588) according to the manufacturer’s recommended protocol.
Immobilized proteins were visualized by incubation with a working solution of 5-bromo4-chloro-3-indoyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) ("Rapid
measurement of protein concentration by western analysis using colorimetric detection by
bcip-nbt," 2006). Alkaline phosphatase detected VDS immune complexes were estimated
using a purified wildtype enzyme standard curve and ImageJ software (Figure 2.4)
(Schneider et al., 2012).
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Figure 2.4 Quantitation of wildtype and mutant VDS enzyme amounts in cell lysates. Cell
lysates were prepared from E. coli cells induced for expression of the VDS or mutant genes
and 20 µg of total protein separated by SDS-PAGE prior to transferring to nitrocellulose
(right panel). The blots were incubated with mouse polyclonal anti-polyHistidine antibody
conjugated with alkaline phosphatase and immune complexes detected using colorimetric
reactions with BCIP/NBT (5-bromo-4-chloro-3-indoyl-phosphate/nitro blue tetrazolium,
respectively) as substrates. The immune complexes were captured using ImageJ software
and quantification calculated against standard curves constructed using purified wild type
VDS (left panel).
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2.3

Results and Discussion

2.3.1

Building an Accurate 3D Structural Representation of VDS

To target amino acid residues within VDS which might govern product specificity,
an energy-minimalized model of VDS was rendered upon the molecular coordinates of the
TEAS-FHP-Mg2+3 complex (PDB: 5eat) (Starks et al., 1997) using MODELLER (Sali &
Blundell, 1993) (Figure 2.5, Panel A). The VDS model exhibited the classical “terpene
fold” consisting of 𝛼𝛼 -helices connected by loops and turns adopting the 𝛼𝛼𝛼𝛼 domain

architecture (Figure 2.5, Panel A) (Christianson, 2017; Lesburg et al., 1997; Starks et al.,

1997). The active site cavity (shape analogous to a cylinder) measured approximately 14.1
Å tall (Trp286 to Asp318) by 10.9 Å wide (Ser311 to Asp539) (total volume of 1316 Å3)
surrounded by predominantly non-polar amino acid residues, akin with previously
crystallized sesquiterpene synthases (Figure 2.5, Panel B) (Lesburg et al., 1997; Starks et
al., 1997; Tarshis et al., 1994). The model’s C⍺’s deviated by 2.154 Å with 92 % of its
atoms within 3.5 Å of their structural positions in TEAS (referred to as native overlap
(Eramian et al., 2008)). Finally, we identified the evolutionarily conserved 𝛼𝛼-helices in the
COOH terminus through superimposition of the TEAS crystal structure (Figure 2.5, Panel

A). Using the default scoring function of Autodock Vina (Trott & Olson, 2010), we
anchored FPP (MOPAC energy-minimalized (Stewart, 2016)) into the VDS active site
using the restricted search space of 1 Å spacing with a 15 Å grid box. We generated nine
theoretical binding confirmations of FPP, all with similar binding energies (-7.7 to -7.9
kcal/mol). To visually determine the most reasonable spatial orientation of FPP, we aligned
the TEAS-FHP-Mg2+3 complex with each of the VDS-FPP complex models for visual
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inspection. Of the nine theoretical binding confirmations, one binding confirmation, #6,
geometrically docked FPP in the characteristic “U” shape with the terminal pyrophosphate
group anchored between the tri-nuclear magnesium cluster, angled towards the G1/G2
helix break (Figure 2.6). With our substrate docked in a feasible orientation and an accurate
3D molecular model of VDS, we set out to establish the amino acid residues forming the
active site topography. Through a cavity detection radius constrained to 7 Å and cavity
detection cutoff at three solvent radii, we identified twenty-four residues which formed the
solvent inaccessible active site shell, structurally poised to influence the catalytic trajectory
of VDS (Figure 2.5, Panel B).
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Figure 2.5 (A). In silico 3D structural superimposition of energy minimalized VDS tertiary
model (NH2 terminus - orange rods; COOH terminus - green rods; GenBank: AGB05610
(Yeo et al., 2013)) and the template crystal structure TEAS (NH2 terminal residues - yellow
rods; COOH terminal residues - blue rods; PDB:5EAT) (Starks et al., 1997). Red circle
highlights VDS’ proposed catalytic pocket. (B). VDS’ active site cavity complexed with
Mg2+3 - FPP (Mg2+3 atoms (red spheres); FPP carbon atoms (gray), phosphorous atoms
(orange), and oxygen atoms (red); “DDXXD” and “NSE/DTE” metal-binding domains are
colored in yellow and purple, respectively; J-K and A-C loops are colored in orange and
red, respectively). (C). Snapshot of proposed H+ donor residues within VDS interacting
with 9 (blue sticks) and 13 (red sticks) and other active site residues. Tyr535’s - OH group
(J-K loop) is 3.8 Å (blue dotted line) and 4.3 Å (red dotted line) from C7 on 9 and 13,
respectively. Cys452’s SH group (H2/3 helix) is 10.5 Å (blue dotted line) and 11.9 Å (red
dotted line) from C7 on 9 and 13, respectively. Cys415’s carbonyl group is approximately
5.0 Å (blue dotted line) and 5.8 Å (red dotted line) from C7 on 9 and 13, respectively. (D).
Back side view of VDS displaying the influence on active site topology (grey meshwork)
by select residues flanking the two metal-binding domains resulting in either the 1,10 or
1,11 initial ring closures of 1 (1,10 forms 3 – blue; 1,11 forms 4 – red). Trp286 (C helix),
Ile307 (D helix), Tyr417 (G2 helix), and Leu420 (G2 helix) form the bottom of the active
site cavity. Asn455 is structurally aimed at C1 on 4, while Thr310 and Ser311 (D helix)
are poised at C12,13 on 3.
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Figure 2.6 Superimposition of the TEAS-FHP ribbon structure (blue) (PDB 5EAT) (Starks
et al., 1997) onto the selected energy-minimized VDS-FPP model (green) generated with
Modeller (Sali & Blundell, 1993) and Autodock Vina (Trott & Olson, 2010) programs. The
overlay image of the TEAS-FHP and VDS-FPP structures was made using PYMOL v1.8
(Delano Scientific, South San Francisco, CA) (Schrodinger, 2015). Note the close overlap
between FHP (yellow) and FPP (grey), the “U” shape of both, and the juxtaposition of C10
and C11 in proximity to the initial carbocation that will be generated at C1. The three
magnesium ions (red spheres) are located near the entrance to TEAS’ active site poised to
ionize the phosphate group on FHP, thus initiating the catalytic cascade.
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2.3.2

Selection Criteria for Candidate Residues

Recognizing terpene product specificity is predominantly determined by those
residues lining the active site, we chose to restrict our candidate selection to primarily 1st
tier residues identified by our contact map strategy (Figure 2.5, Panel B).(Greenhagen et
al., 2006; Yoshikuni, Ferrin, et al., 2006) Several residues classified as 1st tier residues with
well-documented catalytic roles in sesquiterpene synthases were excluded from
consideration because of their essential contributions to the general catalytic process
(Figure 2.5, Panel B): Arg277 conserved among all terpene synthases and necessary for
offsetting the negative charge from the ionized pyrophosphate group of FPP (Starks et al.,
1997); Trp286 is responsible for active site contour and stabilization of carbocation
intermediates through 𝜋𝜋-cation interactions (Christianson, 2017); Asp314 part of class I
terpene synthase conserved metal binding domain (DDXXD motif) which is necessary for

Mg2+ coordination and catalysis (Kersten et al., 2015); Asp459 part of class I terpene
synthase 2nd metal binding domain triad (NSE/DTE motif) necessary for the Mg2+
coordination and catalysis (Aaron & Christianson, 2010) (Figure 2.5, Panel B).
Instead, we focused on residues inferred to be associated with two other biochemical
and structural criteria: 1) residues with the capability of initiating the second half reaction
of VDS’s catalytic cascade via donation of a proton across a double bond; and 2) residues
surrounding the metal binding domains that could restrict substrate binding confirmations.
Previously, our group postulated cysteine and tyrosine residues, structurally aligned to
interact with the substrate, are capable of acting as catalytic acids through the donation of
a proton from their hydroxyl or thiol side chains to re-initiate the catalytic cascade at a
stable reaction intermediate (Greenhagen, 2003). This was further supported by site32

directed mutagenesis studies, which demonstrated that a loss of the residue’s proton donor
functional group halted the catalytic cascade at a neutral reaction intermediate limiting
continuation of the cyclization cascade to the final hydrocarbon product (Greenhagen,
2003; Rising et al., 2000). With this rationale, we sought to map the potential proton donor
amino acid residues within VDS. From our contact map, we identified residues Cys415
(G1/G2 helix break), Cys452 (H helix) and Tyr535 (J/K loop) as potential proton donor
candidates warranting further investigation (Figure 2.5, Panel B).
Several research groups have found that while mutating residues within the metal
binding domains of terpene synthases often leads to loss of enzyme activity, targeting the
residues just outside these domains diversify the product specificity (Abdallah et al., 2018;
Fang et al., 2017; Rynkiewicz et al., 2002; Salmon et al., 2015; Yoshikuni, Martin, et al.,
2006). When we compared the locations of the 1st tier residues with respect to VDS’ two
metal binding domains (D314 DTYD318 & D459 GE467), we selected Ile307, Thr310, Ser311
and Asn455 as potential candidates which look to restrict FPP’s binding confirmation
through hydrogen bonding, van der Waals interactions, and substrate steric hinderance,
thus poised to directly influence the catalytic outcome. From our 3D homology model, we
noticed these residues appear to exert the greatest regio– and stereo-chemical control over
FPP binding conformations, making them prime candidates for our site-directed
mutagenesis study (Figure 2.5, Panel B).
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Figure 2.7 Alignment of amino acid residues mutated within VDS and representative class
I sesquiterpene synthases. The “DDXXD” and “NSE/DTE” metal binding domains are
highlighted in gray. The numbering corresponds to the amino acid positions within VDS.
Alignments were performed with the Multiple Sequence Comparison by Log-Expectation
(MUSCLE) alignment package (v3.8.31) within the MacVector software program (version
18.1.5), and the C-terminal domains of AaADS: Artemisia annua amorpha-4,11-diene
synthase (GenBank: AAF61439); AaBFS: Artemisia annua beta-farnesene synthase
(GenBank: AAX39387); AaBCS: Artemisia annua beta-caryophyllene synthase
(GenBank: AAL79181); GaDCS: Gossypium arboretum delta-cadinene synthase
(GenBank: AAA93065); NtEAS: Nicotiana tabacum 5-epi-aristolochene synthase
(GenBank: AAA19216); ObGDS: Ocimum basilicum germacrene-D synthase (GenBank:
AAV63786); PdBCGS: Phyla dulcis bicyclogermacrene synthase (GenBank: AFR23369);
ScGAS: Solidago canadensis germacrene-A synthase (GenBank: CAC36896); VoVDS:
Valeriana officinalis valerena-1,10-diene synthase (GenBank: AGB05610); ZmACS: Zea
mays alpha-copaene synthase (GenBank: AAX99148).
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2.3.3

Evaluation Procedure for Candidate Residues

We utilized a well-documented in vivo terpene screening platform (Bell et al., 2014;
Nybo et al., 2017) to detect and quantify the various sesquiterpene reaction products
generated by the 1st tier residue mutants while expressed in a living host cell. Briefly,
expression plasmids with the mutant VDS genes were transformed into E. coli cells and
incubated for 24 h with a n-dodecane overlay designed to “capture” the hydrophobic,
volatile reaction products. At 24 h, small aliquots (1 µL) of the dodecane layer were
injected onto a GC-MS for product detection, identification (Figure 2.2 & Figure 2.3) and
quantification (Table 2.2). We evaluated each mutant’s ability to alter VDS’ product
specificity by comparing the percent change in the sesquiterpene product distribution
compared with wildtype VDS’ percent reaction product distribution, providing a relative
measure of the mutant’s activity compared with wildtype. Mutants which were active and
demonstrated at least a 10 % shift from VLD (17) (66 % of the wildtype’s sesquiterpene
products) were considered for further enzyme characterization. Results from all the
mutants evaluated in this work are shown in Table 2.2. For the mutants which met our
criteria in the in vivo screen, we confirmed their reaction products by a secondary in vitro
product profile assay, using the cleared crude lysate from freshly transformed E. coli cells
as our source of enzyme. Results from the in vitro reactions are summarized in Table 2.3
and generally agree with our in vivo results Table 2.2. However, it should be noted
discrepancies in the percent product distributions between our in vivo and in vitro reactions
are likely attributed to the presence of various TPS conformers present in the in vivo assay
yet absent in our in vitro reactions. This is directly correlated to the E. coli cell’s protein
degradation pathways (Sauer & Baker, 2011). Finally, we characterized each mutants’

35

steady-state kinetic parameters using a radiolabeled [1-3H] FPP assay (1-60 µM) (Figure
2.8). We chose to use the crude cleared lysate as our enzyme source for the kinetic assays
due to the potential loss of catalytic activity during the purification process (Bell et al.,
2014). For validation of our experimental accuracy, we compared the crude lysate of
wildtype VDS against the purified wildtype VDS’s kinetic parameters and observed no
significant difference in their KM (µM) values (20.1 vs. 29.8 µM clarified lysate and
column purified, respectively), but approximately a 50 % reduction in the purified
enzyme’s turnover rate, kcat (s-1), (0.018 vs. 0.009 s-1 clarified lysate and column purified,
respectively, Figure 2.9). For kcat determinations, we calculated each mutant’s
concentration in pmoles within the crude lysate with reference to a standard curve
constructed with purified VDS detected by immunodetection against their N-terminal
polyHistidine tag (Figure 2.4). Although the in vitro assays were incubated for 16 h,
shorter incubation periods gave similar product profiles, only with less total product yield
(Figure 2.10).
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Table 2.2 Comparison of the In Vivo Reaction Products from WT and Mutant VDS
Enzymes
Amino Acid Position in VDS

In Vivo % Product Distributions & Total Sesquiterpene Productivity

307 310 311 415 452 455 531 535
WT

I

T

S

C

C

N

M

Y

I307L

L

T

S

C

C

N

M

Y

T310A

I

A

S

C

M

N

M

Y

T310I

I

I

S

C

M

N

M

Y

T310M

I

M

S

C

M

N

M

Y

T310S

I

S

S

C

C

N

M

Y

S311Aa

I

T

A

C

C

N

M

Y

S311Ia

I

T

I

C

C

N

M

Y

S311Fa

I

T

F

C

C

N

M

Y

S311Ta

I

T

T

C

C

N

M

Y

C415A

I

T

S

A

C

N

M

Y

C415S

I

T

S

S

C

N

M

Y

C452A

I

T

S

C

A

N

M

Y

N455A

I

T

S

C

C

A

M

Y

N455C

I

T

S

C

C

C

M

Y

N455S

I

T

S

C

C

S

M

Y

5c

7d

8d

tr.b
tr.b

Unkf

9c

tr.b

29

5

66

69

17

14

40

4

tr.b

3

tr.b

41

tr.b

4

51

13
3

27

I

T

S

C

C

T

M

Y

I

A

S

C

C

S

M

Y

M531L

I

T

S

C

C

N

L

Y

86

M531V

I

T

S

C

C

N

V

Y

73

Y535F

I

T

S

C

C

N

M

F

6

80

10

48

12

15d

16d

17c,e Totalg

6
tr.b

51

12

37

51

tr.b

49

65

tr.b

1.96
1.76

25

tr.b

5

M2

14d

56

61

6

N455T

12d

62

tr.b

65

11c

tr.b

tr.b

tr.b

10d

4
tr.b

11

13

22

tr.b

tr.b

tr.b

10

12

tr.b

tr.b

10

tr.b

18

5

31

3

1.16

31

1.96

tr.b

0.63

7
14

3

tr.b

0.63

tr.b
12

tr.b

tr.b

0.85

14
tr.b
100

27
0.48

Product distributions were calculated as percentages of individual peak areas in relation to
the total peak areas and quantified relative to a caryophyllene standard. gThe total
sesquiterpene productivity (Total) was calculated by averaging the individual
sesquiterpene productivities (mg/L/OD600) from three independent bacterial cultures
measured after 24 h of aerobic fermentation at 28º C and is reported for only select mutants.
The gold and light blue shadings signify codon mutations to neutral or proton donor amino
acid residues, respectively. Colored product numbers correspond to their structural
assignment and catalytic cascade cation route (germacrenyl (red), humulyl (blue), and
helmintogermacrenyl (green)) in Figure 2.1. aNo detected sesquiterpene products; below
GC-MS limit of detection. bTrace amounts (tr.) represent less than 1% of the detectable
reaction products. Product identifications are based upon comparisons to cauthentic
standards, dmass spectral comparisons found in the NIST library 2.0, or those reported by
e
Yeo et al. (Yeo et al., 2013). fMass spectrum of unknown sesquiterpene alcohol (Unk) can
be found in Figure 2.3.
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Table 2.3 Steady-State Kinetic Parameters and In Vitro Product Distributions (%) by WT
and Mutant VDS Enzymes
Steady-State Kinetic Parameters

In Vitro Product Distribution (%)

WT

KM
(μM)
20.1 ± 7.8

kcat
(sec-1)
0.018 ± 0.003

kcat/KM
(µM-1s-1 )
8.96 X 10-4

T310A

12.4 ± 4.2

0.007 ± 0.001

5.65 X 10

-4

5b

7c

8c

Unke

9b

10c

5

22

28

tr.a

9

12

39

tr.a

55

tr.a

63

tr.a

11b

12c

14c

15c

16c 17b,d
44
35

T310M 22.8 ± 11.3 0.002 ± 0.0003** 8.77 X 10-5
C452A 20.7 ± 9.5 0.038 ± 0.008** 18.4 X 10-4
Y535F 9.35 ± 2.75 0.005 ± 0.0004* 5.35 X 10-4
N455A 6.79 ± 2.04 0.020 ± 0.0002** 2.95 X 10-4

23

90

tr.a

tr.a

tr.a

tr.a

10

N455S

-4

91

tr.

tr.

tr.

a

tr.a

9

93

tr.a

tr.a

tr.a

7

10.6 ± 4.3

0.007 ± 0.001

6.60 X 10

N455S,
20.8 ± 6.08
T310A

0.007 ± 0.0007

3.37 X 10-4

6

11

8

19

4
20

92
a

a

tr.a

Colored product numbers correspond to their structural assignment and catalytic cascade
cation route (germacrenyl (red), humulyl (blue), and helmintogermacrenyl (green)) in
Figure 2.1. aTrace amounts (tr.) represent less than 1% of the detectable reaction products.
Product identifications are based upon comparisons to bauthentic standards, or cmass
spectral comparisons found in the NIST library v2.0, or those reported by dYeo et al. (Yeo
et al., 2013) eMass spectrum of the unknown sesquiterpene alcohol (Unk) can be found in
Figure 2.3. Error bars ±SEM. One-way ANOVA using Dunnett’s multiple comparisons
was performed to determine the statistical differences between the observed WT’s KM, kcat,
& kcat/KM to those of the mutants. *P < 0.05, **P < 0.005.
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Figure 2.8 Michaelis-Menten plots of wild type and mutant VDS enzymes. Crude lysates
were used as enzyme source and the amount of VDS protein in each was calculated from
their immune detection as noted in Figure 2.4.
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Figure 2.9 Comparison of steady-state kinetics of wild type VDS from clarified bacteria
lysate (squares) and his-tagged column purified wildtype VDS (circles). VDS protein
amounts were quantified for the clarified lysate as in Figure 2.4 and for the purified VDS
using the Bradford assay. The purified protein gave a single protein as evident from
Coomassie Blue stained PAGE (data not shown), while the VDS protein in the clarified
lysate was evident amongst many other soluble proteins.
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VLD (1.1mg/L)
BCG (0.6mg/L)

4.70 4.90 5.10 5.30 5.50 5.70 5.90 6.10
Retention Time (min)
Figure 2.10 GC chromatogram of the detected hydrocarbon products from a single in vitro
reaction with 100-500 ng of purified VDS and 10 µM FPP incubated for 2 h at room
temperature overlaid with n-hexanes, as detailed in Yeo et. al. (Yeo et al., 2013). Valerena1,10-diene (VLD) and bicyclogermacrene (BCG) productivities were estimated with a
caryophyllene external standard. Note, ~60 % VLD’s and ~30 % BCG’s percent product
distribution is consistent with the results listed in Table 2.2 & Table 2.3 for wildtype VDS’
product distribution profile, observed at 16 and 24 h, respectively.
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2.3.4

Tyr535 is likely the proton donor in VDS

Following the same biochemical rationale as Rising et. al. (Rising et al., 2000), we
mutated Tyr535 (J/K loop, 4.3 or 3.8 Å from C7 of either 9 or 13, respectively) to a
phenylalanine residue (Figure 2.5, Panel C). This afforded us the ability to maintain the
spatial geometry previously provided by the tyrosine residue in the active site, all the while
removing any potential contribution of a proton donation into the active site matrix. From
our modeling and previous terpene mechanism studies, we hypothesized this mutation
would halt the cyclization cascade at one of the proposed stable intermediates within
VLD’s catalytic cascade (9 or 13, Figure 2.1) (Rising et al., 2000). From our in vivo assay,
we detected bicyclogermacrene (9), identified by its mass fragmentation pattern compared
to an authentic standard provided by F. Bohlmann (Jakupovic et al., 1987) (Figure 2.11),
as 100 % of the reaction products (Table 2.2). This is a significant shift from wildtype
VDS’ product distribution percentages which naturally produces 66 % of 17, 5 % of 10
and 29 % of 9 (Table 2.2, Figure 2.10). In vitro, Y535F’s substrate affinity constant, KM,
improved to half of that for wildtype VDS (9.35 vs. 20.1 µM), while its turnover rate, kcat,
decreased about 3-fold (0.005 vs. 0.018 s-1) and its overall catalytic efficiency (kcat /KM)
decreased to ~60 % of that relative to the wild type VDS (Table 2.3).
Could 9 be the neutral stable intermediate in VLD’s catalytic cascade? According to
Paknikar et. al. (Paknikar et al., 2013), it is conceivable to propose Tyr535 reprotonates C7
of 9. Thus, allowing the concomitant formation of the aromadenrenyl-like cation and
permitting the catalytic cascade to continue onto 17. However, such a conclusion is
tempered by the conservation of Tyr535 amongst other sesquiterpene synthases, including
a bicyclogermacrene synthase (PdBCGS) in Figure 2.7 (Attia et al., 2012; Bennett et al.,
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2002; Bouwmeester et al., 2002; Cai et al., 2002; Chen et al., 1996; Iijima et al., 2004;
Starks et al., 1997; van Der Hoeven et al., 2000). If Tyr535 is the Brønsted acid in VDS’
active site which re-initiates the catalytic cascade, then it might be a unique feature of VDS
and not serve such a role in other bicyclogermacrene synthases. Additionally, our previous
efforts to elucidate putative VDS’s reaction intermediates using 13C labeling revealed the
biogenic origin of VLD’s unique isobutenyl tail likely arose from formation of a C1 to C11
bond, which could proceed through a caryophyllenyl carbocation intermediate or the
germacrenyl cation intermediate as suggested by Paknikar et al. (Paknikar et al., 2013)
(Figure 2.1, Figure 2.13) (Yeo et al., 2013). The involvement of a caryophyllenyl
intermediate in the biogenesis of sesquiterpenes containing this enigmatic isobutenyl side
chain was first proposed by Connolly et. al. (Connolly et al., 1984) studying unique
sesquiterpene carbon structures isolated from liverworts. Conversely, 9’s biogenic carbon
skeleton arises from the initial C1 to C10 bond formation from the all trans-farnesyl
carbocation (1). This is subsequently followed by concomitant deprotonation at C1 of the
germacrenyl cation intermediate (3) leading to bond formation between C1 and C11 and
yielding the bicyclogermacrene (9) intermediate (Figure 2.1) (S. Garms et al., 2010).
According to the mechanistic model of Paknikar et al. (Paknikar et al., 2013), 17 can form
from

the

bicyclogermacrene

intermediate

via

an

energetically

unfavorable

cyclopropylcarbinylcation- cyclopropylcarbinylcation rearrangement (CCR), a mechanism
utilized by eukaryotes in the biosynthesis of triterpenoids, and useful in medicinal and
industrial applications (Blagg et al., 2002; Kempinski & Chappell, 2019; Kempinski et al.,
2019; Niehaus et al., 2011). This model is also consistent with the 13C labeling studies of
Yeo et al. (Yeo et al., 2013) (Figure 2.13). Taken all together, VDS appears to be a
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promiscuous enzyme which generates multiple reaction products, a precedent reported for
many other terpene synthases (S. Garms et al., 2010; Vattekkatte et al., 2017; Yoshikuni,
Ferrin, et al., 2006). And, the results from the Y535F mutation suggest that Y535 might
indeed be responsible for initiating proton donation to the bicyclogermacrene intermediate,
leading to the CCR (Poulter & Rilling, 1978) and formation of 17 as the final reaction
product. Also arguing for the germacrenyl cation pathway for the biosynthesis of 17 is that
no mutants yielding significant amounts of alpha-humulene (5) or beta-caryophyllene (11)
were uncovered. While such a negative result cannot be taken as conclusive evidence that
the humulyl cation pathway for the biosynthesis of 17 doesn’t exist in VDS, the Y535F
mutant is fully consistent with the importance of the germacrenyl cation in the biosynthesis
of VLD (17).
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Figure 2.11 GC-MS comparisons of bicyclogermacrene (9) standard from Jakupovic et.
al. (Jakupovic et al., 1987) with the extracted chemistries from E. coli transformed with the
Y535F mutant.

45

Figure 2.12 Metabolite comparisons of E. coli cells expressing either wildtype VDS,
mutant, or empty vector plasmids. Aliquots of a dodecane overlay are compared by GC.
Gray dashed lines indicate products that accumulate in common amongst bacterial
lines. Peak numbers correspond to the assigned reaction products in Figure 2.1. *Peak of
an unknown sesquiterpene alcohol that co-elutes with 9.
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Figure 2.13 Overlay of the observed and predicted 13C labeling pattern (blue spheres) from
Yeo et. al. onto the revised catalytic cascades of Figure 2.1. The labeling pattern
documented for 17 arising from the cyclization of 13C-labeled FPP (1) by VDS is consistent
with either the humulyl (blue) or germacrenyl (red) pathways.
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2.3.5

Probing the role of Cys415 and Cys452

From our previous efforts to alter product specificity of terpene synthases
(Greenhagen et al., 2006), we hypothesized that if a TPS reaction cascade is truncated at a
stable intermediate, then its catalytic turnover rate and efficiency should be at least
comparable to (if not greater than) the wildtype enzyme such as we observed with the
C440A mutant from EAS (Greenhagen, 2003; Greenhagen et al., 2003). We combed the
active site residues of VDS from our constructed contact map, searching for a cysteinyl
sulfhydryl positioned to interact with the β isoprene unit of FPP and discovered Cys415,
located within the G1/G2 Helix break region (Figure 2.5, Panel B). Baer et al. (Baer et al.,
2014) identified and characterized the G1/G2 Helix Break “effector triad” - a conserved
structural motif comprised of three amino acids among all bacteria, fungi, and plant class
I terpene synthases responsible for the induced fit between the synthase and substrate
aiding in the transition from the open to the closed confirmation. In the VDS homology
model, Cys415’s carbonyl group is structurally positioned in the “effector” position (3.7 Å
from C3 on FPP) could be responsible for triggering the cleavage and release of the
diphosphate of FPP to form the delocalized allylic carbocation (1), while residues Ser414
(linker) and Arg456 (pyrophosphate sensor) comprise the rest of the effector triad (Figure
2.5, Panel C). To explore the catalytic role of Cys415, we substituted the thiol containing
residue for an alanine and serine residue and profiled the reaction products in vivo (Table
2.2). Both mutations exhibited a dramatic decrease in total productivity with an
approximate 50 % diversion of the catalytic specificity from 17 to 9. Because neither
C415A, nor C415S eliminated the production of the primary reaction products found with
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the wildtype enzyme, it is unlikely Cys415 is directly involved in the active site acid-base
chemistry.
From the homology model, Cys283(C Helix) and Cys452 (H Helix) are positioned
11.9 and 10.5 Å from C7 on 9 and 13, respectively (Figure 2.5, Panel C). However, we
narrowed our focus to Cys452 instead of Cys283, since it is positioned similarly to Cys270
in EAS (PDB: 5EAT) and appears to be involved in the formation of an active site hydrogen
bond network with Tyr541 and the creation of an essential structural feature in VDS (Starks
et al., 1997). We removed the proton donor capabilities of Cys452 by an alanine mutation
and characterized the reaction products both in vivo and in vitro. The in vivo analysis
detected a product distribution for C452A of 31 % valerenadiene (17), 65 %
bicyclogermacrene (9) and 4 % allo-aromadendrene (10), similar to the product profile
shift of the C415A and C415S mutants (Table 2.2). However, the KM for the C452A
mutant (20.7 µM) is identical to VDS (20.1 µM), but its kcat of 0.038 s-1 is double that for
VDS (0.018 s-1) which translates to a doubling in the catalytic efficiency (kcat /KM) of
C452A (Table 2.3).
The failure of C452A to completely shift the product specificity of VDS towards 9
is not consistent with its role as the Lewis acid in donating a proton to intermediate 13 in
the VDS catalytic cascade (Figure 2.1). An alternative is that a water molecule may be
trapped in the active site serving as the requisite proton donor, a hypothesis that cannot be
ruled out for VDS (Christianson, 2017; Felicetti & Cane, 2004; S. Garms et al., 2010;
Grundy et al., 2016; Rynkiewicz et al., 2002; Yoshikuni, Martin, et al., 2006). Perhaps
Cys452 is contributing more to active site topology guiding catalytic outcomes. The
analogous position within the previously characterized bicyclogermacrene synthase (Attia
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et al., 2012) (Figure 2.7) is occupied by a leucine residue, located just outside the active
site on Helix H (Figure 2.5, Panel B & C), which may offer sufficient influence on the
active site contour to steer the catalytic activity more specifically towards 9. A logical
inference from this interpretation would be to evaluate a C452L mutation in VDS for its
product specificity and catalytic efficiency.

2.3.6

Contributions of residues proximal to a metal binding domain

. Several research groups have demonstrated that residues surrounding the metal
binding domains found within amorpha-4,11-diene synthase (ADS), can contribute to both
the initial and subsequent ring closures of ionized FPP in the formation of the amorphenyl
cation, directly impacting product specificity and catalytic activity (Abdallah et al., 2018;
Fang et al., 2017; Li et al., 2016). Hence, we investigated Ile307, Thr310 and Ser311, the
analogous residues proximal to the DDXXD metal binding domain in VDS (Figure 2.7).
To begin evaluating the contribution of the hydrophobic surface comprised of these
residues to the catalytic activity, Ile307 associated with the D Helix was substituted with a
leucine. This position resides within the hydrophobic core deep within the VDS’ active site
along with Trp286, Tyr417, and Leu420 (Figure 2.5, Panel D). Interestingly, an I307L
mutation, a mutation of a conserved residue, resulted in almost a 60 % decline in relative
activity without any change in overall product specificity other than a shift in the ratio of
products, greater than 35 % increase in the amount of 9 accumulating and concomitant
decrease in 17 (Table 2.2). Due to the buried nature of this residue within the active site,
the loss of activity with a highly conserved mutation and the conserved nature of the Ile at
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this position amongst terpene synthase (Figure 2.7), no further mutations at this site were
investigated.
Thr310 and Ser311 are situated above the first aspartate residue of the DDXXD motif
oriented towards the active site pocket and juxtaposed relative to the 𝛾𝛾-isoprene unit of
FPP, potentially poised to influence orientation of the initial farnesyl carbocation and

control of the ensuing catalytic cascade (Figure 2.5, Panel B). Consistent with the essential
nature of these particular residues (Figure 2.7), all attempts to mutate Ser311 with
hydrophobic (alanine and isoleucine), polar (threonine), or aromatic (phenylalanine)
mutations lead to inactive VDS mutants (Table 2.2). However, substitution mutants of
Thr310 with alanine, isoleucine or methionine residues yielded catalytically active
enzymes with alterations in the proportion of valerenadiene (17), bicyclogermacrene (9)
and allo-aromadendrene (10) (Table 2.2 & Table 2.3), except that the methionine mutant
(T310M) also generated a new product, 𝛼𝛼-gurjunene (12) in 27 % abundance. While this

particular mutant maintained a KM (22.8 µM) for FPP comparable to the wildtype enzyme,
its catalytic turnover rate (kcat) was only about 1/10th of the wild type VDS (Table 2.3).
The Thr310 mutations are consistent with the germacrenyl cation pathway as the
dominate pathway for the biosynthesis of VLD (17). Other than the T310S mutant, which
was largely inactive, mutations to non-polar residues like alanine, isoleucine or methionine
shifted the product profile to greater proportions of bicylcogermacrene (9), consistent with
Thr310 being a gateway residue for the conversion of bicyclogermacrene (9) onto VLD
(17). The extra bulk contributed by the T310M mutant would also be consistent with this
mutant allowing the bicyclogermacrene (9) intermediate to initially proceed down the
catalytic cascade, but to be diverted to a novel product, α-gurjunene (12), because the
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active site was constrained from performing the CCR. Schrepfer et al. (Schrepfer et al.,
2016) used a similar logic in mapping functionally plasticity residues within taxadiene
synthase, a type I diterpene synthase.

2.3.7

Asn455 suppress a dormant cyclization cascade in VDS

Based on the report of Nguyen et al. (Nguyen et al., 2016) that a valine to glycine
mutation within a β-farnesene synthase was sufficient to convert product specificity from
linear to complete cyclized products, we examined the possible role of the analogous
position within VDS, 455 (Figure 2.7), to contribute to possible intermediate formation in
the VLD cascade. When Asn455 was substituted for alanine, cysteine, serine or threonine,
the resulting mutant enzymes possessed only 12 to 25 % of the wildtype enzyme activity
and produced greater than 40 % of germacradien-4-ol (7) as the majority product. This is
in contrast to VDS, or the other mutants mentioned above which only yield a small
percentage of 7. However, more surprising was that much of the remaining products
resulting from these mutants were ⍺-copaene (14), 𝛿𝛿-cadinene (15), cubebol (16), products

that can only arise for an all trans to cisoid confirmation change of FPP to nerolidyl
diphosphate, NPP (Figure 2.1, green arrow route). Moreover, these mutants also lost their
ability to produce 9 and 17. While none of the Asn455 mutants accumulated products that
could be interpreted as intermediates for either of the possible catalytic pathways to 17,
these mutants appear to be confirming an important evolutionary role for this position in
the cyclization pathways of type 1 sesquiterpene synthases as suggested by Salmon et al.
(Salmon et al., 2015).
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2.4

Conclusions
While the experimental aim of this work was to find mutants of VDS that produced

cyclic derivatives with alternative configurations of the iso-butenyl side chain or more
structurally constrained analogs of the valerenadiene scaffold, the work has established a
map of residues impacting catalytic outcomes, including a mutant producing exclusively
bicyclogermacrene (Y535F) and identified Asn455 as serving as a gatekeeper for
sesquiterpene products requiring a configurational isomerization of FPP to the cisoid
precursor NPP. These results help focus future efforts in creating more constrained
scaffolds for building analogs to test for their modulatory activity of the human GABAA
receptor and anxiolytic activities in animal models.
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CHAPTER 3. TOWARDS BUILDING A VALERENIC ACID ANALOG
BIOSYNTHESIS PLATFORM IN YEAST
3.1

Introduction
Our second objective was to produce at least three to four structurally constrained,

carboxylated valerenadiene analogs for evaluation of their human GABAA receptor
biological activity in a mammalian cell based GABAA receptor host system with a voltage
sensitive fluorescent dye (CHAPTER 4). However, given our unsuccessful attempts to
uncover VDS mutants which derail to more structurally constrained intermediates
(CHAPTER 2), we shifted forward towards establishing a robust S. cerevisiae host
platform capable of producing VA (Figure 3.1). It should be noted, a synthetic route to
VA has been established and was considered as an alternative to obtaining the structurally
constrained oxidized compounds; however, this strategy suffers from arduous reactions,
costly reagents, and low substrate to product conversion rates (Ramharter & Mulzer, 2009).
Therefore, we conducted our work in our ZXB yeast line (Zhuang & Chappell, 2015), as
opposed to our current E. coli chassis for the following reasons: 1) ZXB contained a
dispensable FPP substrate pool (Zhuang & Chappell, 2015) - the acyclic carbon backbone
of all sesquiterpenes (Cane, 1990), 2) it possessed an endoplasmic reticulum (ER), the
cellular organelle which anchors the N-terminal transmembrane domain of terpene
modifying cytochrome P450 enzymes (Pateraki et al., 2015; Williams et al., 2000), and 3)
ZXB’s parental yeast strain, 178-08 (Chappell et al., 2021; Zhuang & Chappell, 2015),
produced over 500 mg/L of a kaurenoic acid (Zhuang, 2013) - a successively oxidized
terpene involved in the gibberellin biosynthetic pathway (Helliwell et al., 1998) – from
episomal expression of kaurene synthase (a diterpene synthase (Yamaguchi et al., 1996;
Yamaguchi et al., 1998)), kaurene oxidase (a cytochrome P450 responsible for the

successive oxidation at C19 (Helliwell et al., 1999)), and a NADPH dependent cytochrome
P450 reductase (Takahashi, Yeo, Greenhagen, et al., 2007).
Recently Chappell and company investigated the tailoring enzyme(s) involved in
VA’s biosynthetic pathway using an Agrobacterium rhizogenes transformed hairy root
culture system developed from valerian leaf explants (Ricigliano et al., 2016).
CYP71D442, a putative terpene specific cytochrome P450 with an approximately 4-fold
higher mRNA expression level in mature roots versus leaf and stem regions of wildtype V.
officinalis, was hypothesized to play a significant role in VA biosynthesis. However, it was
ruled out after its mRNA expression levels decreased, while mRNA levels increased for
FPP and VDS in valerian hairy root cultures challenged with methyl jasmonate (Ricigliano
et al., 2016). Despite the recent heroic efforts from the Chappell group, the native valerian
enzyme(s) responsible for the oxidation of VA remain unknown.
To circumvent the arduous and labor-intensive task of functionally identifying the
endogenous tailoring enzymes involved in VA biosynthesis, we explored an alternative
strategy reported by the Ro group. Nguyen and company initially probed the substrate
promiscuity of a germacrene A oxidase (GAO) cloned from lettuce (Lactuca sativa) and
spiny barnadesia (Barnadesia spinosa) for subsequent oxidation at carbon atoms trans to
double bonds on seven different sesquiterpenes containing a two-ring core structure
(Nguyen et al., 2019). These investigators reported that both isoforms of the GAO enzyme
successively oxidized the terminal methyl substituent on VLD’s isobutenyl side chain to
form the bona fide VA chemical structure (Nguyen et al., 2010; Nguyen et al., 2016;
Nguyen et al., 2019). Hence, their discovery provided an approach for adding the
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(Figure 2.1, Structure #17) in the trans position on VLD’s isobutenyl sidechain without
reliance upon re-capitulation of the native VA biosynthetic pathway from V. officinalis.
A hypothetical reaction scheme for successive oxidation of a desired constrained
sesquiterpene scaffold, synthesized from the cyclization of FPP, involving a single
cytochrome P450 enzyme or an assembly of tailoring enzymes, is shown in greater detail
in Figure 3.2.
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Figure 3.1 VA and VA analog factory in our ZXB yeast host system. (Bottom pathway)
The ZXB yeast host platform was utilized to constitutively express extrachromosomal
copies of VDS from the xLEU – GPDp(VoVDS);TEFp(VoVDS) plasmid for de novo
synthesis of VLD from FPP, the acyclic carbon precursor. VLD was then successively
oxidized to a carboxylic acid at its terminal methyl group (colored in blue) located on its
isobutenyl side chain by the endomembrane-bound (brown shape) catalytically
promiscuous germacrene A oxidase from lettuce (LsGAO). Electrons are transferred from
NADPH to LsGAO through the cytochrome P450 reductase from sweet wormwood
(AaPOR). (Upper pathway) Once in hand, our goal is to co-transform separate plasmids
encoding for the desired VDS mutant enzymes in our ZXB host system with the xHISGPDp(LsGAO);TEFp(AaPOR) plasmid for successive oxidation at one of the VLD
constrained analog’s terminal methyl groups (colored in blue) to form the carboxylic acid.
The red highlighted C-C bonds show the location of structural constraint from either
cyclization or a reduction in rotatable bonds in comparison with VLD’s flexible isobutenyl
side chain.
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Figure 3.2 In this hypothetical reaction oxidation scheme, the linear substrate FPP is first
cyclized into the desired constrained sesquiterpene intermediate. Then, the hydrocarbon
intermediate is trafficked to an endomembrane-bound cytochrome P450, where molecular
oxygen is inserted at an allylic carbon atom to form the primary alcohol. The oxygenated
intermediate is either oxidized to the aldehyde by the same P450 or through an alcohol
dehydrogenase (ADH). Finally, the aldehyde intermediate is oxidized for the second time
to the carboxylic acid by either the initial P450 or by an aldehyde dehydrogenase (ALDH)
enzyme complex. For VA formation, both routes (successive oxidation by a single
cytochrome P450 enzyme or by a set of tailoring enzymes) have been posited, but none
proven to date (Ricigliano et al., 2016; Wong et al., 2018).
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3.2

Materials and Methods

3.2.1

Chemicals and reagents

Acetone, n-dodecane, n-hexanes, and ethyl acetate were of ACS reagent grade and
purchased through Fisher Scientific (Waltham, MA). Yeast synthetic drop-out medium
lacking histidine, leucine, tryptophan, and uracil, hereafter referred to as SC (Cat # Y2001),
and D-glucose (Cat # G8270) were all purchased from Sigma Aldrich (St. Louis, MO).
Ergosterol (Cat #117810050) was purchased from Acros Organics (Fair Lawn, NJ). NMethyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) + 1% Trimethylchlorosilane
(TMCS) (Cat# RMB1204) was purchased from Ricca Chemical Company (Arlington, TX).
TRI Reagent® (Cat # TR 118) was purchased from Molecular Research Center and kept
at 4º C as instructed. Superscript III First-Strand Synthesis System for RT-PCR by
Invitrogen (Cat # 18080-051) was purchased through Fisher Scientific and kept at -20º C
as recommended.
3.2.2

VoVDS cloning and amplification

The xLEU-GPDp;TEFp expression plasmid, described in Zhuang’s dissertation
work (Zhuang, 2013), was employed to express multiple extrachromosomal copies of the
VDS gene for constitutive VLD production. The VoVDS gene was first amplified by PCR
from the pET28(a)-VoVDS vector (Yeo et al., 2013) with a gene specific forward and
reverse primer (Integrated DNA Technologies) flanked with unique restriction sites at the
5’ and 3’ ends (Table 3.1, primer #’s 1 & 2; 3 & 4) using PrimeSTAR HS DNA
polymerase (Takara Bio), according to the manufacturer’s recommendations. Additionally,
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the forward primer harbored the partial Kozak sequence “AAAACA” between the 5’
restriction site and the start methionine. The amplified VoVDS gene was verified by sizing
via gel electrophoresis and the appropriate band was purified using the QIAquick Gel
Extraction Kit (Qiagen) according to the manufacturer’s recommendations. The purified
VDS insert, and the empty xLEU- GPDp();TEFp() vector were subjected to double
restriction digestion with the appropriate restriction enzymes (Figure 3.3, A), ligated into
the appropriate expression vectors using T4 DNA Ligase (Promega), followed by
transformation into the E. coli DH5α cell line. Positive transformants were selected on
growth media plates containing 50-100µg/mL of ampicillin. Individual colonies were
subsequently screened for recombinant plasmids using restriction digestion followed by
DNA termination sequencing.
3.2.3

LsGAO amplification and cloning

Wildtype lettuce (Lactuca sativa) plants were grown in ProMix BX (Premier Tech)
soil under a 16hr light/ 8hr dark cycle using Sylvania OCTRON 6500K bulbs in a
greenhouse. To prevent bolting, plants were grown in a laboratory setting with minimal
temperature and humidity fluctuations. After 4-5 weeks of growth, 2-3 leaves were
harvested and immediately flash frozen in liquid nitrogen. The harvested leaf tissue was
homogenized, and total RNA was isolated with Tri Reagent® (Molecular Research
Center), following the manufacturer’s protocol. Quality of the isolated RNA was evaluated
by agarose gel electrophoresis and the concentration estimated by a nanodrop
spectrophotometer (Thermo 2000c). cDNA first-strand synthesis was carried using oligo
dT’s and Superscript III Reverse Transcriptase (Invitrogen), per the manufacturer’s
instructions. The LsGAO cDNA was PCR amplified with primers “5” and “6” in Table
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3.1. The amplified DNA of 1400-1500bp was gel purified for subsequent ligation in the
into the xHIS-GPDp();TEFp(AaPOR) vector (Zhuang, 2013) at the 5’-EcoRI & 3’-NotI
cloning sites (Figure 3.3, B). The DNA constructs was verified by DNA termination
sequencing.
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Table 3.1 List of VoVDS and LsGAO forward and reverse cloning primers
Primer

Sequence (5' to 3')

Name

1

GCGGCCGCAAAACAATGGAGAGTTGCCTTAGTTTTTCAAG

NotI-Kozak-VoVDS
(Fwd)

2

ACTAGTTTAATACGGAACACTTTCTACTAGAAG

VoVDS-SpeI (Rev)

3

GGATCCAAAACAATGGAGAGTTGCCTTAGTTTTTCAAG

BamHI-KozakVoVDS (Fwd)

4

GTCGACTTAATACGGAACACTTTCTACTAGAAG

VoVDS-SalI (Rev)

5

GGAATTCAAAACAATGGAGCTTTCAATAACCACCTCCATTGCT

EcoRI-Kozak-LsGAO
(Fwd)

6

ATAGTTTAGCGGCCGCCTAAAAACTCGGTACGAGTAACAACTCAGTC

LsGAO-NotI (Rev)
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Figure 3.3 Molecular constructs co-transformed into the ZXB yeast line for de novo
synthesis of valerenic acid. (A) The valerenadiene synthase (VoVDS) gene were amplified
off of the pET28(a)-VDS construct (Yeo et al., 2013) with a forward and reverse primer
listed in Table 3.1 and subcloned into a modified pescLeu backbone (Zhuang, 2013) under
the glyceraldehyde-3-phosphate (GPDp) and the translational elongation factor EF-1 alpha
(TEFp) independent, divergent promoters for constitutive VLD production. B) The
promiscuous germacrene A oxidase from lettuce (LsGAO) was amplified from an isolated
L. sativa cDNA pool and ligated into xHIS backbone (Zhuang, 2013) under the GPDp
promoter using primer #’s 5 & 6 Table 3.1. To transfer electrons from NADPH to LsGAO,
the cytochrome P450 reductase from the artemisinic acid biosynthetic pathway (Ro et al.,
2006) (AaPOR) was previously amplified from isolated A. annua cDNA pool and ligated
into xHIS backbone under the TEF promoter (Zhuang, 2013).
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3.2.4

S. pyogenes Cas9-NLS amplification and cloning

To construct the xLEU-GPDp(Cas9-NLS)ADH1t plasmid (Figure 3.4, A) the
human codon-optimized version DNA coding sequence of Cas9 fused at its carboxy
terminus to the simian virus 40 nuclear localization signal (SV40 NLS), originally isolated
from Streptococcus pyogenes (Jinek et al., 2012; Mali et al., 2013), was amplified from the
p414-TEF1p-Cas9-CYC1t vector with primers “7” and “8” listed in Table 3.2. The p414TEF1p-Cas9-CYC1t plasmid (DiCarlo et al., 2013) was a gift from George Church
obtained from Addgene (plasmid #43802). Using standard restriction enzyme cloning (RE
cloning) procedures described previously, the Cas9-NLS gene was positioned under the
GPD (TDH3) promotor by ligation at the 5’-NotI, 3’-SpeI restriction sites within the
xLEU-GPDp;TEFp empty vector (Zhuang, 2013). Verification of correct insertion of the
Cas9-NLS gene was confirmed by single-pass nucleotide sequencing analyzed at the UK
HealthCare Genomics Core Laboratory.

3.2.5

BTS1, Rox1, YPL062W, & YJL064W gRNA cassettes

Synthetic DNA sequences coding for the entire guide RNA (gRNA) expression
cassette including the promoter, target sequence, gRNA structural components, and
terminator (Table 3.3) were synthesized as gene fragments (gBlocks®) by Integrated DNA
Technologies (Coralville, IA). The nucleotide sequences for the tRNATyr promoter, gRNA
scaffold, and SNR52 terminator, were taken directly from Ryan et. al. (Ryan et al., 2014)
(Table 3.3). The target gRNA sequences for the Saccharomyces cerevisiae
BTS1(YPL069C), Rox1(YPR065W), YPL062W, and YJL064W genomic sites were copied
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directly from Jakociunas et. al. (Jakociunas et al., 2015). For constitutive, high-level
expression in yeast, the gRNA cassettes were amplified with primers 9 & 10 (Table 3.2)
and cloned in at the BamHI/HindIII restriction sites within the xURA-GPDp();TEFp()
empty vector (Zhuang, 2013)

3.2.6

Homology-armed VDS DNA oligo

The dsDNA repair template was constructed from standard molecular techniques of
PCR and SOE (splicing by overlap extension) PCR (Heckman & Pease, 2007). Using a
two-step PrimeSTAR HS DNA Polymerase PCR (Takara) protocol, the 500bp homologous
regions upstream and downstream of the yeast BTS1, Rox1, YPL062W, and YJL064W
genomic loci, were attached to appropriate ends of the GPDp(VDS)ADH1t gene blocks
(Figure 3.4, C). Primer #’s 11-16, 17-22, 23-28, and 29-34 (Table 3.2) were used to attach
the BTS1, Rox1, YPL062W, and YJL064W 500bp homology arms to the
GPDp(VDS)ADH1t gene block, respectively. ZXB genomic DNA, isolated following the
protocol described within (Harju et al., 2004), served as the PCR template for cloning the
500bp homologous DNA strands up- and down-stream of the four targeted yeast loci. The
BTS1, Rox1, YPL062W, and YJL064W yeast genomic sequences were copied directly from
www.yeastgenome.org.
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Figure 3.4 Molecular constructs used to knock out specific yeast genomic loci and replace
with single copies of a constitutive VDS expression construct. (A) A yeast codon optimized
version of the S. pyogenes Cas9 gene (SpCas9) fused at its C terminus to the SV40 nuclear
localization signal (SV40 NLS) (Jinek et al., 2012) was amplified from the p414-TEF1pCas9-CYC1t vector (DiCarlo et al., 2013) with primer #’s 7&8 (Table 3.2) and positioned
under the GPD promoter (GPDp) in the xLEU-GPDp()ADH1t empty vector (Zhuang,
2013) using RE cloning. (B) The BTS1, Rox1, YPL062W, & YJL064W gRNA structural
cassettes were constructed as double-stranded DNA gene blocks (Integrated DNA
Technologies) and RE cloned into the xURA-GPDp()ADH1t empty backbone (Zhuang,
2013) with primer #’s 9&10 (Table 3.2). (C) The GPDp(VDS)ADH1t DNA oligo (minus
the homology arms) was amplified from the xLEU-GPDp(VoVDS);TEFp(VoVDS) vector
(Figure 3.3, A) with the primer #’s 11&13, 14&16 - BTS1; 17&19, 20&22 – Rox1;23&25,
26&28 – YPL062W; 29&31, 32&34 - YJL064W (Table 3.2) and subsequently, gel purified.
The 500bp up- and downstream homology arms were amplified from ZXB genomic DNA
with the primer #’s 11&13, 14&16 - BTS1; 17&19, 20&22 – Rox1;23&25, 26&28 –
YPL062W; 29&31, 32&34 - YJL064W (Table 3.2), then purified by gel electrophoresis.
The flanking homology arms were subsequently sown onto the GPDp(VDS)ADH1t
amplicon using the primer pair #’s 11&16 – BTS1; 17&22 – Rox1; 23&28 – YPL062W;
29&34 –YJL064W (Table 3.2) in a two-step PCR protocol.
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Table 3.2 List of CRISPR/Cas9 cloning primers
Primer

Sequence (5' to 3')

Comment

7

ATGCGGCCGCAAAACAATGGACAAGAAGTACTCCATTGGGC

NotI-Kozak-pCas9 (Fwd)

8

ATACTAGTTCACACCTTCCTCTTCTTCTTGGGG

pCas9-SpeI (Rev)

9

ATTGGATCCGTATACTCTTTCTTCAACAA

BamHI-tRNATyr-prom (Fwd)

10

TAAAAGCTTTATCCACTAGACAGAAGTTT

HindIII-SNR52-term (Rev)

11

AGCATTATCAAAAAGCTTGACAAGC

BTS1 upstream (Fwd)

12

GGAGGCCAAGATAGATGAGCAGTTTATCATTATCAATACT

BTS1 upstream GPDp (Fwd)

13

AGTATTGATAATGATAAACTGCTCATCTATCTTGGCCTCC

BTS1 upstream GPDp (Rev)

14

GGTATAGCATGAGGTCGCTCTGGTCCAGCCAAAATGAAAG

BTS1 downstream ADH1t (Fwd)

15

CTTTCATTTTGGCTGGACCAGAGCGACCTCATGCTATACC

BTS1 downstream ADH1t (Rev)

16

ATGAGTCTCAACGTTAATCTGAAAAGG

BTS1 downstream (Rev)

17

ACTTGGCGATTGCTGACAAAGAAGAAAAG

Rox1 upstream (Fwd)

18

TCTGTTCAGACAGCACTACCAGTTTATCATTATCAATACT

Rox1 upstream GPDp (Fwd)

19

AGTATTGATAATGATAAACTGGTAGTGCTGTCTGAACAGA

Rox1 upstream GPDp (Rev)

20

GGTATAGCATGAGGTCGCTCTGGACCGCTCAAGGTGTGGA

Rox1 downstream ADH1t (Fwd)

21

TCCACACCTTGAGCGGTCCAGAGCGACCTCATGCTATACC

Rox1 downstream ADH1t (Rev)

22

AGTTGAGATGACAGCTGTGGTAGGTC

Rox1 downstream (Rev)

23

TCATTTTGTTACTGTCATGTGAATAAAACTTATG

YPL062W upstream (Fwd)

24

TACCATTGTAGAAGCAACCAAGTTTATCATTATCAATACT

YPL062W upstream GPDp (Fwd)

25

AGTATTGATAATGATAAACTTGGTTGCTTCTACAATGGTA

YPL062W upstream GPDp (Rev)

26

GGTATAGCATGAGGTCGCTCAGGTCTCCTCTTGCCCGGGC

YPL062W downstream ADH1t (Fwd)

27

GCCCGGGCAAGAGGAGACCTGAGCGACCTCATGCTATACC

YPL062W downstream ADH1t (Rev)

28

ATTTATATATGATATCAAGAACTTGTTAAACACGCC

YPL062W downstream (Rev)

29

TTGATATATTTGTCATTAAATGCCTTGG

YJL064W upstream (Fwd)

30

TGCGGCAGAGATGTCATCGTAGTTTATCATTATCAATACT

YJL064W upstream GPDp (Fwd)

31

AGTATTGATAATGATAAACTACGATGACATCTCTGCCGCA

YJL064W upstream GPDp (Rev)

32

GGTATAGCATGAGGTCGCTCGGGAGCGGCGGTACCTGTTG

YJL064W downstream ADH1t (Fwd)

33

CAACAGGTACCGCCGCTCCCGAGCGACCTCATGCTATACC

YJL064W downstream ADH1t (Rev)

34

GTCTACTCTTCGTCATTGCCAAAGAAG

YJL064W downstream (Rev)

35

CGGTAGGTATTGATTGTAATTCTG

GPDp sequencing promoter (Fwd)

36

GAGTCACTTTAAAATTTGTATACAC

ALDH1t sequencing promoter (Rev)
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Table 3.3 BTS1, Rox1, YPL062W, & YJL064W gRNA cassette nucleotide sequences
gBlock

Sequence (5' to 3')

Name

1

GTATACTCTTTCTTCAACAATTAAATACTCTCGGTA
GCCAAGTTGGTTTAAGGCGCAAGACTGTAATTTAT
CACTACGAAATCTTGAGATCGGGCGTTCGACTCGC
CCCCGGGAGAGCACGTCGCCGTGGCTGATGGTTTT
AGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTG
CTTTTTTTATTTTTTGTCACTATTGTTATGTAAAATG
CCACCTCTGACAGTATGGAACGCAAACTTCTGTCT
AGTGGATA

tRNAtyrProm-BTS1gRNA-SNR52t

2

GTATACTCTTTCTTCAACAATTAAATACTCTCGGTA
GCCAAGTTGGTTTAAGGCGCAAGACTGTAATTTAT
CACTACGAAATCTTGAGATCGGGCGTTCGACTCGC
CCCCGGGAGAACAGGATCTTAATAGACGAAGTTTT
AGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTG
CTTTTTTTATTTTTTGTCACTATTGTTATGTAAAATG
CCACCTCTGACAGTATGGAACGCAAACTTCTGTCT
AGTGGATA

tRNAtyrProm-Rox1gRNA-SNR52t

3

GTATACTCTTTCTTCAACAATTAAATACTCTCGGTA
GCCAAGTTGGTTTAAGGCGCAAGACTGTAATTTAT
CACTACGAAATCTTGAGATCGGGCGTTCGACTCGC
CCCCGGGAGATGATCAATAATGATCCTGTTGTTTTA
GAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCC
GTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC
TTTTTTTATTTTTTGTCACTATTGTTATGTAAAATGC
CACCTCTGACAGTATGGAACGCAAACTTCTGTCTA
GTGGATA

tRNAtyrProm-YPL062WgRNA-SNR52t

4

GTATACTCTTTCTTCAACAATTAAATACTCTCGGTA
GCCAAGTTGGTTTAAGGCGCAAGACTGTAATTTAT
CACTACGAAATCTTGAGATCGGGCGTTCGACTCGC
CCCCGGGAGAACGACAGCGTGAGTTCATCTGTTTT
AGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTG
CTTTTTTTATTTTTTGTCACTATTGTTATGTAAAATG
CCACCTCTGACAGTATGGAACGCAAACTTCTGTCT
AGTGGATA

tRNAtyrProm-YJL064WgRNA-SNR52t

The tRNA tyrosine promoter (tRNAtyrProm), BTS1, Rox1, YPL062W, and YJL064W
target sequences, gRNA structural scaffold, and the SNR52 terminator (SNR52t) coding
nucleotide sequences are colored in red, blue, green, and black, respectively.
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3.3

Construction and maintenance of utilized yeast lines

3.3.1

ZXB yeast line

Details on how the ZXB yeast line (Table 3.4) was generated can be found in
(Chappell et al., 2021; Zhuang & Chappell, 2015). Briefly, the BY4741 parental yeast line
was first subjected to unbiased ethyl methanesulfonate mutagenesis, then subsequently
grown on media containing nystatin, squalestatin, and exogenous cholesterol to select for
yeast lines having a dispensable mevalonate biosynthetic pathway and an ability to take up
exogenous sterols to meet their metabolic needs under aerobic condition. Further genetic
modifications included gene knockout of Erg9 (squalene synthase) and the replacement of
Erg1 (squalene epoxidase) with a catalytically improved version of 3-hydroxy-3methylglutaryl-CoA reductase (HMGR), the rate-limiting step in the sterol biosynthetic
pathway (Chappell et al., 1995).
For routine culturing, wildtype ZXB colonies were grown on YPG-E solid agar
plates (10g/L Yeast extract, 10g/L Peptone, and 20g/L Glucose, supplemented with 4mL/L
of a 10mg/mL Ergosterol stock solution – 0.5g ergosterol dissolved in 50mL of a 1:1
ethanol:triton-x-100 solution) (Zhuang & Chappell, 2015). The VoVDS and LsGAO
:AaPOR expression constructs (Figure 3.3, A &B) were co-transformed into ZXB using
the standard lithium acetate method (Gietz & Woods, 2002; Liu et al., 2017), described in
detail below:
A single, ≤5-day old, ZXB colony was inoculated into 3-5 mL of YPG-E liquid

media (10 g/L Yeast extract, 10 g/L Peptone, and 20 g/L Glucose, supplemented with

0.5mL/L of a 10mg/mL Ergosterol stock solution, pH 5.3-5.5) in a 14mL centrifugation
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tube and incubated at 28°C, while shaking at 230 RPM for 24-48 hrs. The next morning,
the culture’s optical density at 600nm was measured and subsequently diluted down to a
OD600 0.1-0.3 in 2xYPG-E. The culture was incubated in the 28°C with shaking for two
growth cycles, which took six to eight hours. Once the culture density reached an OD600 of
0.4 – 1.2, cells were pelleted by centrifugation at 3000xg for 5min at room temperature.
The cell pellet was washed with sorbitol wash buffer (1.2M sorbitol solution buffered with
potassium phosphate (pH 7.5)) by pipetting up and down with a 1mL pipet. The cells were
pelleted again, then gently washed with 100 mM lithium acetate (1 mL) and pelleted for a
third time. The lithium acetate layer was carefully removed, and the yeast cells carefully
resuspended in 3.55 mL of the pre-filtered transformation buffer – 100µL of 10mg/mL
denatured salmon sperm DNA stock, 360µL of a 1M lithium acetate, 690µL of distilled
water, and 2400µL of a 50% PEG 4000 (w/v) stock solution. 200 µl of the competent yeast
cell resuspension was mixed with 0.5-1.0 µg of the yeast expression constructs from
(Figure 3.3, A&B), followed by heat-shocking at 42°C for 15-60min. Afterwards, the cells
were pelleted by centrifugation (6000xg, 15min, room temperature), resuspended in 200µL
of filter-sterilized, double-distilled water, then dispersed across SCG-E (SC+ 20g/L
Glucose + 4mL/L of the Ergosterol stock solution) solid media plates with the omission of
one or two auxotrophic markers – L-leucine (leu), L-histidine (his). The plates were kept
at 28°C until colony formation (typically three to four days). Colonies selected for chemical
analysis were re-streaked onto fresh SCG-E selection plates every five days. Note: all wash
buffers and reagents, except for the 10mg/ml denatured salmon sperm DNA, were prepared
fresh weekly, then filtered through a sterile 0.25µm PES membrane and kept at 4°C or on
ice prior to the yeast transformations. Double-stranded salmon sperm DNA (Invitrogen)
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(10 mg/ml) was denatured in a 96°C water bath for 5min and aliquots stored at -20°C until
needed for transformations.

3.3.2

CRISPR/Cas9 engineered yeast lines from ZXB

The GZyBTS1, GZyRox1, GZyYJL064W , and GZyYPL062W yeast lines (Table
3.4) were generated by co-transforming 1µg of the xLEU-GPDp(Cas9-NLS)ADH1t
plasmid (Figure 3.4, A), with 1µg of xURA-TEFp(tRNAtyrp-(Target Site-gRNASNR52t)CYCt (Figure 3.4, B), onboarded with 0.4-0.6µg of the GPDp(VDS)ADH1t DNA
oligo template (Figure 3.4, C) into the ZXB parental yeast line following a standard
lithium acetate protocol previously described (Figure 3.5). The transformed yeast cells
were dispersed across SCG-E solid media plates with omission of leucine and uracil amino
acids and stored at 28°C until colonies appeared, typically three to four days later. Colonies
selected for chemical analysis were re-streaked onto fresh SCG-E selection plates every
five days.
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Table 3.4 Genotypes of yeast lines used in this study
Strain

Parent (+ additional genetic changes)

Reference

BY4741

MATa;his3Δ1;leu2Δ0; met15Δ0; ura3Δ0

(Brachmann et al., 1998)

ZXB

BY4741 (SUE;HPH:Δerg9;tHMGR-KanMX4: Δerg1)

(Zhuang & Chappell, 2015)

GZyBTS1

ZXB (GPDp-VDS-ADH1t:ΔBTS1)

This study

GZyRox1

ZXB (GPDp-VDS-ADH1t:ΔRox1)

This study

GZyYPL062W

ZXB (GPDp-VDS-ADH1t:ΔYPL062W)

This study

GZyYJL064W

ZXB (GPDp-VDS-ADH1t:ΔYJL064W)

This study
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Figure 3.5 CRISPR/Cas9-DNA Repair System was used to perform simultaneous genomic
knock out and knock in with VDS expression construct in yeast. The Cas9 gene and gRNA
expression cassettes (for the four target loci) were cloned into and expressed from
auxotrophic vectors (Figure 3.4, A & B), respectively. The VDS DNA repair template
(Figure 3.4, C) was constructed from the primers listed in Table 3.2, then co-transformed
with the Cas9 and gRNA expression cassette plasmids at equal molar ratios into chemically
competent ZXB cells.
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3.4

Detection of VLD and VA from engineered yeast lines
3.4.1

Plasmid-based expression system

Yeast co-transformed with the xLEU-GPDp(VoVDS);TEFp(VoVDS) (Figure 3.3,
A)

and

xHIS-GPDp(LsGAO);TEFp(AaPOR)

(Figure

3.3,

B)

plasmids

were

auxotrophically selected on SCG-E (-leu, -his) agar plates, then subsequently cultured in
3mL of liquid SCG-E (-leu, -his) media buffered with 100mM HEPES pH 7.5 (sterile
filtered) for seven days at room temperature with vigorous orbital shaking. Nguyen et al.
(Nguyen et al., 2010) discovered that when the yeast growth media was buffered between
pH 6-7, acid-induced structural rearrangements, such as hydration and allylic
rearrangements, are minimized leading to increased titers of desired carboxylated
sesquiterpenes (Nguyen et al., 2010; Nguyen et al., 2019), which we mimic in our culturing
methods as well.
After 7 days, 1 mL of the yeast cultures were lysed with 1mL of acetone, and the
culture’s hydrophobic constituents partitioned into 80% ethyl acetate and 20% n-hexanes
spiked with a known amount of (-) cedrene. The glass vials were subsequently vortexed,
then left on the benchtop for 10 – 20 min. Further phase separation was obtained with a
low-speed centrifugation protocol (300xg, 10min, room temperature). Aliquots (1µL) of
the dodecane or organic layer were then injected onto a Agilent 7890 GC programed with
the following parameters: splitless injection; HP-5MS column, 30m x 0.25mm, 0.25μm
film, 250°C inlet temperature; oven temperature was 100°C initially, then increased to
140°C (10°C/min), then increased to 200°C (5°C/min), and finally increased to 300°C
(120°C/min) and held for 5min; 0.9 mL/min He flow rate) connected to a 5975C Agilent
mass spectrometer (run in positive ionization mode, 70 eV, scanning 40-500 amu). VLD
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yields were estimated from a hexadecane standard. Aliquots of the organic layer were also
dried down under nitrogen prior to derivatization MSTFA + 1% TMCS, described below.
To increase the GC-MS sensitivity for detection of VA, we replaced the H atom of
the carboxylic acid group with a trimethyl silane handle using N-Methyl-N(trimethylsilyl)trifluoroacetamide (MSTFA) + 1% Trimethyl chlorosilane (TMCS).
Briefly, an aliquot (100µL) of the organic layer was evaporated off by a low, steady stream
of nitrogen. 30µL of MSTFA + 1% TMCS (Ricca Chemical Company) was added by a
clean glass syringe, vial re-capped, vortexed for 5sec, and then placed in a 50ºC heating
block for 1hr. The vial was removed from the heating block and 70µL of ethyl acetate to
maintain the original sample volume. Then, 1µL of the derivatized sample was analyzed
by GC-MS (method described above). VA yields were estimated with derivatized VA
standard.
3.4.2

CRISPR/Cas9 VDS knock in yeast line system

For confirmation of VDS genomic insertion and subsequent VLD production from
chemically competent ZXB cells co-transformed with the CRISPR/Cas9 molecular
constructs (Figure 3.4 A, B & C), four to five colonies were randomly selected from the
SCG-E growth plates. Then, subjected to colony PCR with primers designed to only
amplify the upstream and downstream homology arms flanking each of the integration sites
(Table 3.2, primer pair #’s - 11 & 16 (BTS1), 17 & 22 (Rox1), 23 & 28 (YPL062W),
and 29 & 34 (YJL064W)) (Figure 3.6). Only PCR-confirmed colonies were then
inoculated into 3mL of YPD-E media with a 10% dodecane overlay in 14mL test tubes.
After 7 days, 1µL of the dodecane layer was subjected to GC-MS chemical analysis and
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VLD titers (mg/L) were estimated with an external hexadecane standard curve, as
described previously.
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Figure 3.6 The VDS DNA expression oligo (Figure 3.4, C) was integrated through the
highly favored HR DNA repair pathway at Cas9 mediated double-strand DNA break sites
within the BTS1, Rox1, YPL062W, and YJL064W genomic loci. Primers which annealed
to the flanking homology arms (Table 3.2, primer pair #’s: 11&16-BTS1, 17&22-Rox1,
23&28-YPL062W, and 29&34-YJL064W) were used to confirm insertion of the
GPDp(VDS)ADH1t DNA oligo by colony PCR. VDS expression DNA oligo + 500bp
homology arms ≈ 3700bp. L, DNA ladder (GeneRuler 1kB Plus, Thermo Fisher); Neg,
amplification from the 500bp upstream to the 500bp downstream homology arms of BTS1
=1000bp; Lanes 1-4, VDS insertion at the BTS1 site; Lanes 5-7, VDS insertion at the Rox1
site; Lanes 8-11, VDS insertion at the YPL062W site; Lanes 12-15, insertion at the
YJL064W site.
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3.5

Results and Discussions

3.5.1

Successive oxidation of valerenadiene to valerenic acid

To confirm the results of Nguyen et al. (Nguyen et al., 2019), we co-transformed the
LsGAO1;AaPOR (Figure 3.3, B) and the VoVDS;VoVDS (Figure 3.3, A) vectors into
chemically competent ZXB yeast cells, generating yeast lines that accumulated 11mg/L
VLD and 1.7mg/L VA, as detected by GC-MS analysis (Table 3.5). For VA structural
confirmation, we compared the EI mass spectra of an authentic, MSTFA + 1% TMCS
derivatized 3ng VA standard (Figure 3.7, Panel A) with a derivatized organic extract
(Figure 3.7, Panel B) from yeast co- transformed with the VDS and GAO vectors (Figure
3.3, A&B) Although our VA titers were nearly two times lower than reported by Nguyen
et. al. (Nguyen et al., 2019), our 16-18% conversion of VLD to VA was three to four times
higher than the recently reported 2.9% to 3.6% within yeast microbial host systems
(Nguyen et al., 2019; Wong et al., 2018), but slightly below 25% in planta (detected within
Ricigliano et al.’s “VoVDS-1” hairy root line (Ricigliano et al., 2016)). Given the low titers
of VLD and VA, but respectable VLD to VA conversion efficiency in the ZXB host system,
we sought to compare the titers in yeast who had VDS expression cassettes inserted into
their genomes at transcriptional safe loci using the CRISPR/Cas9-DNA repair model
(Figure 3.5). We surmised if we could improve the VLD’s titers to 50-60mg/L, then the
concomitant VA titers would fall into the range of 9-11mg/L. Hence, a production platform
for VA analogs yielding sufficient amounts (~10 mg) of constrained acid analogs for
subsequent biological testing might be realized (Figure 3.1).
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Table 3.5 Valerenadiene (VLD) and valerenic acid (VA) titers from plasmids transformed
into ZXB
Yeast Line
ZXB

Transformed Plasmids
xLEU:VDS;VDS
xHIS:GAO;POR
aTiters

VLD Titersa

VA Titersa

% VLD Converted

11.1 ± 1.8

1.7 ± 0.2

15.3 ± 0.2

represent the averages from four independent yeast colonies, mg/L ± SEM.
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Figure 3.7 Retention time and EI mass spectral validation of bona fide valerenic acid (VA)
(Panel B) produced within ZXB transformed with the constructs shown in Figure 3.3, A&B
compared to the 3ng of a valerenic acid standard (Panel A). *Denotes the VA peak. Both
samples were dried completely under nitrogen and subjected to MSTFA + 1% TMCS
derivatization for 60min at 50°C. 1µL aliquots were then injected on a 7890 Agilent GC
tandem arrayed to a 5975C EI-MS for separation (left panels) and detection (right panels).
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3.5.2

Improvement in valerenadiene yeast titers using CRISPR/Cas9

The Chappell lab recently adopted the re-purposed CRISPR (Clustered Interspaced
Palindromic Repeats)/Cas9 (Crispr-associated protein 9) bacteriophage defense system
(Cong et al., 2013; DiCarlo et al., 2013; Jinek et al., 2012) optimized for yeast genome
editing (DiCarlo et al., 2013; Jakociunas et al., 2015; Ryan & Cate, 2014; Ryan et al., 2014)
to produce upwards of 500mg/L of triterpenes (Tateno et al., 2020) within our ZX strain
(Zhuang & Chappell, 2015). Following the work of Tateno et. al. (Tateno et al., 2020), we
simultaneously knocked out and inserted single copies of a GPD promoter driven VDS
expression cassettes (Figure 3.4, C) at four unique genomic loci: BTS1 (Verwaal et al.,
2007), Rox1 (Henry et al., 2002), YPL062W (Chen et al., 2019), and YJL064W (Jakociunas
et al., 2015). Jakočiūnas et. al (Jakociunas et al., 2015) previously reported these genes
encode for proteins which perturb the carbon flux through the mevalonate pathway. For
example, Özaydın et. al. discovered a YJL064W yeast knockout line increased their terpene
titers 40-fold in shake flasks compared to the wildtype strain (Özaydın et al., 2013). The
GZyBTS1, GZyRox1, GZyYPL062W, & GZyYJL064W yeast lines were generated by
inserting single copies of a GPDp-VDS-ADH1t DNA oligo into the BTS1, Rox1,
YPL062W, & YPL064W loci found within the ZXB parental line using a multiplexed
CRISPR/Cas9- DNA repair template method as described by Jakociunas et. al. (Jakociunas
et al., 2015). Colonies, with correct insertion of the VDS expression construct (Figure 3.6),
were subjected to chemical analysis and VLD titers estimated from a hexadecane standard.
The GzyRox1 (18mg/L), GZyYJL064W (19mg/L), and GZyYPL062W (23mg/L) yeast
lines nearly doubled the VLD titers achieved using the plasmid based VDS expression
system (11mg/L) (Table 3.6). On the other hand, when we integrated a single copy of the

81

GPDp-VDS-ADH1t oligo into the BTS1 genomic locus, we observed similar VLD titers
compared with yeast transformed with a plasmid harboring two copies of the VDS gene
(Figure 3.3, A) expressed from distinct independent promoters (10mg/L vs. 11mg/L,
respectively) (Table 3.6). These results may suggest, deletion of yeast loci that encode for
proteins which negatively repress gene expression of enzymes involved in the MVA
pathway or inversely regulate the available acetyl-CoA substrate pool (i.e., YPL062W) is a
productive metabolic engineering strategy for increasing VLD titers in yeast.
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Table 3.6 VLD titers from plasmid expression of VDS vs. chromosomal insertion within
ZXB
Yeast Line

VDS cDNA Expression

VLD Titersa

Statistical Significance

ZXB

plasmid

11.1 ± 1.8b

-

GZyBTS1

integrated

10.1 ± 2.3c

No

GZyRox1

integrated

17.7 ± 0.2c

No

GZyYPL062W

integrated

22.6 ± 1.5c

Yes**

GZyYJL064W

integrated

19.0 ± 0.7c

Yes*

aTiters represent the averages from either 2c or 4b independent yeast colonies, mg/L ± SEM. A one-way ANOVA was
performed using the Dunnett’s multiple comparison between the VLD titers from plasmid expression of the VDS gene
under divergent, independent promoters vs. single-copy chromosomal integration. *P value = 0.0472; **P value =
0.0079.
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3.6

Conclusions
Recently, Wong et. al. (Wong et al., 2018) reported achieving 140mg/L of VLD, the

highest titers to date produced within a genetically modified yeast line with four copies of
a galactose inducible VDS expression construct inserted into transcriptionally active
chromosomal loci (Reider Apel et al., 2017). Yet, their VLD to VA conversion percentage
was less than 3% after combinatorially pairing a candidate cytochrome P450 cloned from
V. officinalis with the alcohol and aldehyde dehydrogenases from the artemisinin
biosynthetic pathway (Paddon et al., 2013). Wong et. al.’s results would suggest simply
increasing VLD concentrations in the cytosol may not correlate to enhanced cytochrome
P450-mediated VLD to VA conversion efficiencies. An alternative interpretation to Wong
et. al’s low VLD to VA conversion efficiency may be the overexpressed candidate P450’s
kinetic parameters were submaximal (i.e., poor substrate affinity for VLD and/or low
catalytic turnover rate), a theory which cannot be ruled out. Hence, a three-pronged
metabolic engineering strategy should be highly considered to increase the downstream
titers of VA – improving cytosolic VLD concentrations by increasing VDS expression
levels, exploring ways to improve the protein-protein coupling efficiency between VDS
and its endomembrane-bound tailoring enzyme(s), while considering ways to enhance the
paired P450s’ substrate affinity and turnover rate (i.e., using directed evolution (Hammer
et al., 2017; Takahashi, Yeo, Zhao, et al., 2007)
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CHAPTER 4. ESTABLISHING & VALIDATING A HUMAN CELL LINE-BASED
FLUORESCENCE ASSAY FOR MODULATION OF THE HUMAN GABAA
𝛼𝛼1𝛽𝛽3𝛾𝛾2L RECEPTOR

4.1

Introduction

Developed in 1976 by Neher and Sakmann, single channel recordings of cellular
membranes expressing ionic channels revolutionized the field of neurophysiology,
allowing researchers to understand and characterize functional excitable neurons (Hamill
et al., 1981; Neher & Sakmann, 1976; Neher et al., 1978). This technology was applied to
transiently expressed GABAA receptors in 1987 by Schofield et al., who proposed GABAA
receptors are part of the ligand-ion superfamily with each subunit containing four
transmembrane domains, forming a selective pore for chloride ions to passively pass
through (Pritchett et al., 1988; Schofield et al., 1987). Schofield and company pioneered
the patch-clamp technique establishing it as the “gold standard” for future work in
functionally characterizing GABAA receptors’ role(s) as the fundamental inhibitory
pathway in the central nervous system (Angelotti et al., 1993; Benke et al., 2009; Jacob et
al., 2005; Jurd et al., 2003; Karim et al., 2013; Klausberger et al., 2001; Low et al., 2000;
Luger et al., 2015; Miller & Aricescu, 2014; Succol et al., 2012; Tretter et al., 1997).
Though patch-clamping is a useful research tool to the field of drug discovery, it naturally
doesn’t bode well for screening libraries of chemistries for their potential
neuropharmacological activities in an expedient manner (i.e. – less than two weeks)
(Obergrussberger et al., 2021). Hence, to streamline ion channel drug discovery,
researchers have optimized fluorescent probes as a way to measure the activity level of
membrane-bound ion channels (Baxter et al., 2002; Fiala et al., 2020; Joesch et al., 2008).
This has afforded pharmaceutical drug researchers the opportunity to screen through

libraries of compounds within a matter of weeks, as opposed to months associated the more
traditional screening methodologies, such as patch-clamping (Neher & Sakmann, 1976).
The class of molecules are typically grouped together based upon their reporting
mechanisms, however; all fall under the more broad category as voltage-sensitive dyes
(VSDs) (Cohen & Salzberg, 1978). One fluorescent dye in particular, DiSBAC13 (Figure
4.1, Structure G), naturally partitions across a living cell’s semi-permeable membrane in
a voltage dependent manner (Baxter et al., 2002; Joesch et al., 2008). When a living cell’s
membrane is depolarized due to flux of chloride ions through a recombinant GABAA
receptor, the DiSBAC13 molecules separate from the membrane impermeable quencher
and move into the phospholipid bilayer, thus becoming available for excitation under
visible light at 𝝀𝝀525nm, capturable with an emission filter set to 𝝀𝝀595nm on a fluorescent plate
reader (Figure 4.2, B). The net change in fluorescence reflects the level of affinity (or
potency) and stimulation (or efficacy) of a given compound in a concentration-dependent
manner for a recombinantly expressed ion channel at the cell surface (Figure 4.2, C).
In the following body of work, the FMP Red dye assay was assessed for its utility to
detect the varying levels of potencies and efficacies from chemistries with known and
unknown activity for the human GABAA receptor (Figure 4.1, Structures A - F). Such an
assay, if suitably validated, would afford investigators the ability to have a rapid and
selective screening tool for combing through libraries of compounds in search of novel
chemistries with potentiation activity for the human GABAA ( 𝛼𝛼1𝛽𝛽3𝛾𝛾2L) receptor. More

specifically, we aimed to evaluate the FMP Red dye assay as a screening paradigm for the
evaluation of chemically constrained VA analogs, which we hope can be produced and
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purified from the yeast production platform described in Chapter 3 (CHAPTER 3) of this
dissertation.
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Figure 4.1 Compounds A-C were used to validate the FMP Red Dye assay for its sensitive
and high-throughput capabilities as a drug discovery screening tool for novel GABAA
receptor (allosteric) modulators (Nik et al., 2017). Compounds D-F were included as
experimental controls to evaluate the structural specificity at VA’s putative binding site(s)
on the TM2 domain within the 𝛽𝛽 3 subunit of the human GABAA receptor (Benke et al.,
2009; Luger et al., 2015). Compound G is the elucidated structure of the fluorescent probe
commercially sold as FMP-Red dye by Molecular Devices (Nik et al., 2017).
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Figure 4.2 Conceptualization of the FMP Red Dye assay used to identify novel modulators
of the human GABAA receptor. A) When the FMP red dye (DiSBAC1(3)(Nik et al., 2017),
red filled circles) is added to the outside of living cell’s, a portion (approximately 25%) of
the DiSBAC1(3) molecules separate from the membrane impermeable quencher (green
arcs, masking dye meant to block the excitation of the DiSBAC1(3) molecules without
interfering with the cell’s biological processes) and intercalate into the phospholipid bilayer
in a voltage dependent manner (Baxter et al., 2002). Only unquenched DISBAC1(3)
molecules are excitable under visible light at 𝝀𝝀525nm, capturable with an emission filter set
to 𝝀𝝀 595nm. B) In the presence of FMP Red dye molecules, exogenously added GABA
(yellow filled circles) binds at the interface of the 𝛼𝛼 & 𝛽𝛽 subunits (orange & blue ovals,
respectively), shifting the GABAA receptor from a “closed” to an “open” state (Karim et
al., 2013; Miller & Aricescu, 2014), concomitantly permitting chloride ions to efflux out
of the cytosol, against their concentration gradient, depolarizing the cell membrane. At the
same time, partially negative DISBAC1(3) molecules separate from the membrane
impermeable quencher and move into (or even through) the plasma membrane, increasing
the fluorescence signal detected from inside the cell (Joesch et al., 2008; Nik et al., 2017).
C) The net change in fluorescence (∆F) is linear with respect to the concentration of bound
GABA molecules and follows the typical dose-response behavior, eventually reaching the
maximal effect once all surface-expressing GABAA receptors are occupied by GABA
(Goodman et al., 2011). Normalized fluorescent traces were calculated from subtracting
the average of three baseline readings taken prior to the addition of GABA (indicated by
the black arrow) from the raw fluorescent values after the addition of GABA.
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4.2

Materials and Methods

4.2.1

Chemicals and reagents

Cyclopartheniol (CPol) was originally synthesized by Dr. Michel Crevoisier at the
University of Berne) (Berne, Switzerland) (Crevoisier et al., 1984) and was a gift from Dr.
Robert Coates at the University of Illinois (Urbana, IL). Gamma aminobutyric acid
(GABA) (Cat# A2129), clonazepam (CZP) (Cat# C1277), 2-cis,4-trans-abscisic acid
(ABA) (Cat# 862169), gibberellic acid (GA3) (Cat# 48880), and molecular biology grade
HEPES (Cat# H4034) were purchased through Sigma Aldrich (St. Louis, MO). Valerenic
acid (VA) (Cat# 3801S) was purchased as lyophilized powder through Extrasynthese
(Genay, France) and kept at -20°C upon receipt. High-purity dimethyl sulfoxide (DMSO)
(Cat# 97063-136) was purchased through the third-party supplier Avantor (Radnor, PA).
The FLIPR Membrane Potential (FMP red dye), which included the membrane
impermeable quencher, was purchased through Molecular Devices (San Jose, CA) (Cat #
R8126) as a freeze-dried powder and kept in the dark at -20°C upon receipt.

4.2.2

Culturing wildtype HEK293 cells

HEK293 cells (ATCC# CRL-1573) were a gift from Dr. Daniel Pack (University of
Kentucky). Frozen vials of cells were thawed and expanded in Dulbecco’s modified
Eagle’s medium (Corning) and 5% fetal bovine serum (Corning or VWR) at 37°C in 5%
CO2. When cells reached 70-80% confluency, they were harvested using 0.05% trypsinEDTA and 1.0-2.0 x 106 cells were placed into a new, sterile T-75 flask. Passage numbers
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used in this study were from 10-20. Twenty-four hours prior to the FMP RED Dye assay,
naïve HEK293 cells were harvested, counted, and seeded in a 96-well black well, clear
bottom imaging plates (Falcon) at 50,000-60,000 cells/well in 100𝜇𝜇L of growth media. The
cells were allowed to adhere for 24hrs.

4.2.3

Culturing transfected HEK293 cells

On day zero, 2,500,000 naïve HEK293 cells were seeded into a 10 cm2 sterile, cell
culture treated dish in Dulbecco’s modified media (DMEM) + 5% fetal bovine serum
(FBS) (growth media). The following day (day one), the cells were transfected using
Lipofectamine 3000 (Invitrogen) with equal amounts (4.8𝜇𝜇g/plasmid) of the pcDNA3.1(+)
– bovine GABAA (⍺1), pcDNA3.1(+) – human GABAA (β3), and pcDNA3.1(+) – human
GABAA (𝛾𝛾2L) plasmids, following the manufacturer’s recommendations. It should be
noted, the bovine GABAA ⍺1 subunit differs only in the signal peptide with the human

GABAA ⍺1 subunit, the mature peptides are identical (Dostalova et al., 2014). The cells

were placed back at 37°C in 5% CO2 to recover for twenty-four hours. The following day
(day 2), the transfected cells were harvested, counted, and seeded into a 96-well black well,
clear bottom imaging plate (Falcon) at 50,000-60,000 cells/well in 100𝜇𝜇L in growth media.
The cells were allowed to attach for 24hrs. Passages used in this study were 11-20. The
bovine and human GABAA receptor plasmids were a generous gift from Dr. Stuart Forman,
Massachusetts General Hospital. Before transfection experiments, the GABAA - ⍺1/ β3 /

𝛾𝛾2L subunit sequences were verified by sanger sequencing (UK HealthCare Genomics
Core Laboratory) using a CMV promoter forward and a bGH poly-A termination signal
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reverse sequencing primer. The DNA coding sequences matched the NCBI GenBank
references: CAA29189.1 (bovine GABRA1); NP_068712.1 (human GABRB3 mRNA
transcript 2); NP_944494.1(human GABRG2 mRNA transcript 1).
For experiments examining the statistical reliability of the HEK 293 cells expressing
the three expression vectors, three 10cm dishes were seeded with wildtype HEK293 cells,
then transfected the next day with three separate preparations of the Lipofectamine 3000
(Invitrogen) mixed with 4.8µg of each 𝛼𝛼1, 𝛽𝛽 3, & 𝛾𝛾2L human GABAA receptor expression

vectors. Care was taken to ensure the three, independently transfected HEK293 cell lines
were kept separated to preserve their biological heterogeneity. Similar experimental design
was used to examine the reliability of independently prepared expression vector DNA and
for experiments examining the ratios of the 3 vectors used in the transfections. The vector
ratios tested included 1:1:1, 2:2:1 and 1:1:10 with the amount of each vector DNA being
adjusted to not exceed the total DNA amount of 14.4 µg.

4.2.4 Culturing HEK293 cells stably expressing human GABAA receptors
HEK293 cells stably expressing the human GABAAR 𝛼𝛼1𝛽𝛽3𝛾𝛾2 subunits (CYL3053

PrecisION hGABA-A 𝛼𝛼1/𝛽𝛽3/𝛾𝛾2-HEK Recombinant Cell Line) was a generous gift from

Dr. Isaac Pessah (University of California). Upon arrival, cells were expanded in
Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, and 1% penicillinstreptomycin at 37°C in 5% CO2. To maintain pressure for cells that only express the
human GABAAR 𝛼𝛼1𝛽𝛽3𝛾𝛾2 subunits, 400 𝜇𝜇 g/mL G418, 100 𝜇𝜇 g/mL hygromycin B,
0.625𝜇𝜇g/mL puromycin was added to the growth media. When cells reached 70-80%
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confluency, they were harvested using 0.05% trypsin-EDTA and 1.0-2.0 x 106 cells were
placed into a new, sterile T-75 flask. Passage numbers used in this study were 10-15.
Twenty-four hours prior to the FMP RED Dye Assay, the cells were trypsinized, collected
by centrifugation, counted by trypan blue exclusion, and seeded in a 96-well black well,
clear bottom imaging plate (Falcon) at 50,000-60,000 cells/well in 100𝜇𝜇L of growth media.
The plate was placed back in the incubator for an additional 24hrs.

4.2.5

FMP RED dye assay 96 well plate preparation

The morning of the assay, a single 96-well imaging plate was removed from the
incubator and the growth media was removed by a swift, jerking-motion. The media
replaced with 100𝜇𝜇L of the Assay Working Buffer #2 (Hank’s Balanced Salt Solution
buffered with 20mM HEPES pH 7.2-7.4 + 0.05% DMSO), hereafter referred to as AWB
#2. Cells were incubated for an additional 3-5min to allow for equilibration. Afterwards, 1
vial of the red membrane potential dye was thoroughly reconstituted with 10.4 mL AWB
#2. 100 𝜇𝜇 L of the FMP-Red-Dye solution was added to each well by an 8-well
multichannel pipet. The plate was then transferred to a CLARIOstar multimode plate reader

(BMG Labtech) and allowed to incubate for 30-40 min to allow for dye penetration and to
minimize the potential photodynamic effects of the voltage-sensitive dye (Mennerick et al.,
2010).
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4.2.6

CLARIOstar optical settings and run mode

Before the assay began, the bottom optic eye was calibrated its optimal positioning.
This ranged from 3.6 to 3.8 for each plate. The gain on the photomultiplier tube was set to
1450 for each study. Each well’s response was recorded via orbital averaging (2mm); the
dye was excited at 510-540nm, and fluorescent signals were recorded at an emission
wavelength window of 566-625nm. Baseline recordings were acquired for eight wells
successively over 15sec (3 cycles total, 35 flashes/well, 5 sec total cycle time) in plate
kinetic mode. The plate was ejected and 50 𝜇𝜇L of the either the AWB #2 (vehicle control)

or a 5x experimental compound was simultaneously added to eight wells using an 8channel pipettor. Responses were recorded within 14 sec of the addition to the well
(instrument delay time in positioning plate) for a total of 60 sec (12 cycles total, 35
flashes/well, 5 sec total cycle time). Individual well responses were calculated as follows:
∆F = Fmax – Fbaseline, where the Fmax was the maximum response in arbitrary fluorescence
units (AFU’s) observed after addition of the AWB #2 or a 5x stock of the experimental

compound and Fbaseline was the average fluorescence before the AWB #2 or a 5x stock of
the experimental compound was added. For comparison of each compound’s ability to
directly activate the recombinant hGABAA receptors, dose-response curves were generated
by plotting the observed ∆F for each compound vs. the final compound concentration (nM)
in the well.
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4.2.7

Immunoblot confirmation of the 𝛼𝛼1, 𝛽𝛽 3, & 𝛾𝛾2L human GABAA subunit total
expression in transfected naïve HEK293 whole cell lysates

2.5-3.0 x106 naive HEK293 cells were seeded in two, sterile 10cm tissue culture
treated petri dishes and transfected with plasmids harboring the cDNA of the human
GABAA receptor 𝛼𝛼 1, 𝛽𝛽 3, and 𝛾𝛾 2L subunits under the cytomegalovirus promoter (CMV)

using Lipofectamine 3000 (Invitrogen), as described above. Forty-eight hours after

transfection, the cells were washed twice with 5 mL of PBS (4°C) and subsequently, lysed
with 0.5 -1.0 mL of 4°C RIPA Buffer (Thermo Fisher) for 5min on ice. The lysed cellular
debris was collected into a sterile, 1.5 mL Eppendorf tube and pelleted by centrifugation
(16,000 x g in a 4°C cold room). The supernatant was transferred to a new, sterile 1.5 mL
Eppendorf tube and total protein amounts was estimated using a bovine serum albumin
standard curve with the Pierce BCA Protein Assay kit (Thermo Fisher). 1, 5 & 15 µg of
the total protein from the transfected hGABAAR (α1 β3 γ2L) HEK293 cells were diluted
in 4X SDS-PAGE Loading Buffer (250mM Tris-HCl (pH 6.8), 8% SDS, 0.2%
bromophenol blue, 40% glycerol, 20% β-mercaptoethanol), denatured in a water bath at
95°C for 5min, centrifuged at 10,000 xg for 5min at 23°C, then loaded and separated on an
8% SDS-PAGE gel. Proteins were transferred to a methanol pre-soaked PVDF membrane
at 4°C for one hour. The membrane was subsequently blocked with a 5% dry milk buffer
(TBST (20mM Tris-HCl (pH 7.6), 150mM NaCl + 0.1% Tween 20) for one hour at 23°C,
then incubated with the appropriate primary antibody overnight, shaking at 4°C. The
following day, the unbound primary antibody solution was discarded, and the membrane
was washed three times in five-minute intervals with TBST. Secondary antibodies
conjugated to HRP diluted in blocking buffer were then added to the appropriate
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membranes and incubated while rocking at 23°C for one hour. The blots were washed again
as described above with TBST. For chemiluminescent detection, blots were incubated for
5-10min with the working solution from the SuperSignal West Pico Plus
Chemiluminescent Substrate kit (Thermo Fisher) and developed on x-ray film in a dark
room (Figure 4.3).
For whole-cell lysate analysis of expression of the hGABAA receptor, we used an
anti-α1 (1:500, Invitrogen, Cat# PA563170, rabbit), anti-β3 (1:2000, BioLegend, Cat#
818501, mouse), anti-γ2L (1:1000, Abnova, Cat# PAB18556, goat), anti-GAPDH (1:10000,
Invitrogen, Cat# TAB1001, rabbit). The goat anti-rabbit (IgG) horseradish peroxidase
(HRP) conjugated secondary antibody used to identify the α1 and GAPDH proteins
(1:20000, Invitrogen, Cat#31460). A goat anti – mouse (IgG) conjugated to an HRP tag
was used to identify the β3 human GABAA subunit (1:20000, KPL, Cat# 5450-0011). The
γ2 GABAA subunit long isoform was detected with a rabbit anti-goat(IgG)-HRP secondary
antibody (1:20000, Invitrogen, Cat# A27014).
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kDa

Figure 4.3 Chemiluminescent blot showing immunodetection of the 𝛼𝛼 1, 𝛽𝛽 3, 𝛾𝛾 2L human
GABAA receptor subunits from whole cell lysates of HEK293 (ATCC# CRL-1573) cells
transfected with Lipofectamine 3000 and equal amounts (4.8µg/plasmid) of the
pcDNA3.1- bovine alpha 1, human beta 3, and human gamma 2L expression vectors.
Antibodies used for detection were 𝛼𝛼1, anti-𝛼𝛼1; 𝛽𝛽3, anti-𝛽𝛽3; 𝛾𝛾2L, anti-𝛾𝛾2L. The black
arrow (top right panel) corresponds to the correct 𝛾𝛾2L band size at ≈54kDa. Loading
control: GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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4.2.8

Data analysis parameters

Log(concentration)-dependent response curves were generated (Figure 4.4) and
statistical analyzed using the GraphPad Prism software v.9. The potency, or EC50, values
were determined using the nonlinear regression mathematical formula with a fourparameter logistic equation within GraphPad Prism (Equation 4.1). Data are presented as
the mean ± SEM from three biological or technical triplicates (stable cell line only).

Unpaired Student’s t-tests were applied to look for statistical differences within the potency
and efficacy means of GABA, CZP, and VA treatments between the transient and stable
GABAA receptor cell lines. The uncorrected Fisher’s Least Significant Differences (LSD)
tests were applied to evaluate the statistical differences between the potency and efficacy
means of GABA, CZP, and VA treatments across HEK293 cells transfected with variable
ratios of the plasmids encoding the 𝛼𝛼1, 𝛽𝛽 3, & 𝛾𝛾2L subunits, 1:1:1, 2:2:1 and 1:1:10.
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Figure 4.4. A) Transiently expressing human GABAA (𝛼𝛼1, 𝛽𝛽 3, 𝛾𝛾2L) receptor HEK293 cells
were challenged separately with 0.1 to 30,000nM of GABA, Clonazepam (CZP), Valerenic
acid (VA), Cyclopartheniol (CPol), Abscisic acid (ABA), and Gibberellic acid (GA3). The
net change in fluorescence (∆F = Fmax - Fbaseline) from three independently transfected wells
were averaged and plotted against the final in-well concentration for each drug/compound
treatment. The fitted sigmoidal curve (solid black line) is shown for the (●) GABA
concentration-dependent response. (inset) Besides GABA, only (☐) CZP and (▲)VA
generated measurable responses above baseline. B) GABA was 40-fold more potent (19.6
nM vs. 808 nM), but 1.5 times less efficacious in HEK293 cells (△) stably vs. (●)
transiently expressing the hGABAA (𝛼𝛼1, 𝛽𝛽3, & 𝛾𝛾2L) receptors. The intersection of the
black dotted lines denotes the calculated potency (EC50) value for each cell line. Exposure
to the vehicle control (VEH, AWB#2) resulted in ∆F’s equivalent or below 1nM of GABA
for the (●) transient and (▲) stable GABAA receptor cell lines. C) For CZP, potency
(8.2nM vs.15.6nM) and efficacy (5332 AFUs vs. 3880 AFUs) were nearly two times and
1.4 times greater for (△) stably vs. (●) transiently expressing hGABAA receptor HEK293
cell lines, respectively. D) The (△) stably vs. (●) transiently expressing hGABAA receptor
HEK293 cell lines exhibited non-statistically different potencies (3687nM vs. 2502nM)
and efficacies (5255AFUs vs. 5935AFUs) to VA challenge.
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𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 = 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 +

(𝑡𝑡𝑡𝑡𝑡𝑡 − 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏)

1 + 10(𝐿𝐿𝐿𝐿𝐿𝐿𝐸𝐸𝐸𝐸50 −𝑥𝑥)𝑛𝑛

Equation 4.1 The four parameter, non-linear regression formula was used to fit
concentration-dependent response curves through the normalized fluorescent responses of
the transient and stable HEK293 cell lines treated with 0.1 – 30,000nM of GABA, CZP,
VA, ABA, CPol, & GA3 (Figure 4.4) for estimating the average potency and efficacy
values of the “active” treatments. Where the response refers to the measured output from a
perturbed biological system; bottom, the lowest observed response; top, the greatest
observed response; EC50, the agonist (drug) concentration which elicits 50% of the
response between the top and bottom boundaries; x, concentration of the drug/compound;
n, hill slope – steepness of the sigmoidal-shaped log (concentration) response curve,
standard value is 1.0.
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4.3

Results and Discussion

4.3.1

Validating heterologously expressed human GABAA (𝛼𝛼1, 𝛽𝛽 3, 𝛾𝛾2L) receptors
display GABA concentration-dependance within the confines of the FMP Red
Dye activity assay

The initial set of experiments were designed to validate the construction of the
fluorescence-based drug discovery platform within HEK293 cells (Figure 4.4), which
would allow corollary evidence to the more laborious patch-clamping studies considered
the gold-standard for measuring perturbations to an ion channel’s physiology (Neher &
Sakmann, 1976) and allow for more rapid screening of chemical libraries for novel
allosteric modulators of the human GABAA (𝛼𝛼 1, 𝛽𝛽 3, 𝛾𝛾 2L) receptor. To substantiate our

experimental protocol and ensure the CLARIOstar’s optical settings were optimized for
the DiSBAC1(3)’s 525nm excitation and 595nm emission wavelengths, we treated the
stably expressing human GABAA receptor HEK293 cell line cells with eight
concentrations of GABA (1-30,000nM). In parallel, naïve HEK293 cells were treated with
1000nM of GABA and exhibited minimal net increases in their fluorescent responses (less
than 1000 AFUs), which were within the background or baseline recordings of the
instrument (Figure 4.5). When the average normalized responses from three biologically
equivalent wells are plotted on a log (concentration)-response curve and a graded doseresponse curve, using the four parameter, non-linear regression equation (Equation 4.1),
fitted through all of the data points, a classical, sigmodal-shaped dose response curve
(Figure 4.4., B) (Goodman et al., 2011) was observed. The GABA EC50 determination is
reported in Table 4.1. When the GABA’s EC50 value determined here is compared to that
of the Pessah research groups (Nik et al., 2017), the GABA potency was two times greater
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in our hands (19.6nM vs. 40.0nM, respectively) (Table 4.1). Interestingly, the GABA
potencies difference were statistically significant by the unpaired Student’s t-test (p <
0.05); however, this didn’t account for outside sources of variation such as the quality of
the reagents, differences in detectors’ fluorescent dye sensitivity, and the overall fitness of
cell line. All of which are imperative parameters to consider while interpreting results from
validated mammalian cell-based drug discovery high-throughput assays, as specifically
outlined by the Assay Guidance Manual (Markossian et al., 2004). Therefore, up to 20%
variation between the reported results from two independent research groups is acceptable
within the context of validating a high-throughput cell-based in vitro assay.
GABA’s 30nM 3 average potency (determined using the FMP Red Dye) was 300 –
1200 fold greater than the potencies reported through patch-clamping of HEK293 cells
recombinantly expressing the same GABAA subunits (𝛼𝛼 1, 𝛽𝛽 3,&𝛾𝛾2L) (6,670nM (Nik et al.,

2017); 36,000nM (Dostalova et al., 2014)). This may likely suggest the voltage-sensitive
DiSBAC1(3) dye within the FMP assay is intrinsically more sensitive in detecting small
voltage changes across the cell’s plasma membrane in comparison with whole-cell patchclamping techniques. An alternative and more widely discussed explanation in the

scientific literature is that the DiSBAC1(3) structure (Figure 4.1, Structure G), along with
the other members of the bis-oxonol slow response dye family, may bind directly at or near
one or more of barbiturate’s two binding sites (located at the interface of the 𝛼𝛼 – 𝛽𝛽 & 𝛾𝛾 –
𝛽𝛽 subunits (Kim et al., 2020)) allosterically potentiating the GABAA receptor (Mennerick

et al., 2010; Nik et al., 2017; Wang et al., 2020). Consistent with this suggestion is the dual-

3

Average of the EC50 values from Chappell (19.6nM) and Pessah (40nM)
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barbituric acid ring core structure (Nik et al., 2017). This anecdotal theory could rationally
explain the greater GABA potencies observed by us and the Pessah research groups. A
critical experiment to help resolve this theory would be to remove or perturb the barbiturate
binding site(s) and re-evaluate GABA’s potency. This could be accomplished by
recombinant expression of the wildtype 𝛽𝛽 3 subunit paired with the 𝛼𝛼S270M & 𝛾𝛾S280M
mutated subunits, observed by Kim et.al. (Kim et al., 2020) to significantly lower
phenobarbital’s allosteric potentiation of the GABAA receptor.
Hence, GABAA receptor potentiation from novel allosteric modulators may also be
masked by or arbitrarily inflated in the presence of the DiSBAC1(3) molecules, without
proper control experiments in place such as, evaluating a range of the candidate
concentrations in the presence and absence of a submaximal concentration of GABA. This
was conducted by Nik et. al. (Nik et al., 2017), who demonstrated a panel of known PAM
neurosteroids and benzodiazepines directly potentiate human GABAA receptors in the
absence of GABA using the FMP Red Dye assay.
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Figure 4.5 Wildtype naïve HEK293 cells (gray line) were seeded at 50,000 – 60,000
cells/well in a 96 black well, clear bottom plate twenty-four hours prior measuring their
responses to 1000 nM of exogenously supplied GABA using the FMP Red Dye assay. The
maximum change in fluorescence of the naïve HEK293 cells (800 AFU at 70 sec) was
about eight times less than HEK293 cells transfected with the human GABAA α1β3γ2L
receptor (4000 AFUs at 70 sec). The response of both naïve and transfected HEK293 cells
to the vehicle control (AWB #2) mirrored the response of the naïve HEK293 cells treated
with 1000 nM GABA (not shown).

104

Table 4.1 GABA potency for the CYL3053 PrecisION hGABA-A 𝛼𝛼1/𝛽𝛽3/𝛾𝛾2-HEK
Recombinant Cell Line independently observed by the Chappell and Pessah research
groups using the FMP Red Dye assay.
Treatment
GABA

Chappell lab a
19.6 ± 6.1

a

Pessah laba,b
40.0 ± 3.5

Potencies are expressed as nM ± SEM; bThe potency standard error the mean (SEM) was derived by dividing the reported standard
deviation (11nM) by the square root of the sample size (10) (Nik et al., 2017)
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4.3.2

Recombinantly expressed GABAA (𝛼𝛼 1, 𝛽𝛽 3, 𝛾𝛾2L) receptors are directly potentiated
by GABA, CZP, & VA in a concentration dependent manner in the absence of
GABA and in the presence of the FMP Red Dye
Having established a reproducible, transient human GABAA (𝛼𝛼1, 𝛽𝛽 3, 𝛾𝛾2L) receptor

expression system in naïve HEK293 cells responsive to GABA potentiation, the next

objective was to characterize the activities of chemistries with known mechanisms of
action: clonazepam (CZP, an FDA-approved benzodiazepine approved to treat PD (Nardi
et al., 2013)) and valerenic acid ((VA), a putative allosteric modulator of the human
GABAA receptors (Benke et al., 2009; Khom et al., 2007; Khom et al., 2010) from V.
officinalis’ root system (Ricigliano et al., 2016; Yeo et al., 2013)). Equal amounts (4.8 µg)
of each plasmid DNA harboring the genes encoding for the 𝛼𝛼 1, 𝛽𝛽 3, 𝛾𝛾 2L subunits were

transfected into naïve HEK393 cells (ATCC # CRL-1573), as described in Section 4.2.3,
and qualitatively verified for the presence of the mature 𝛼𝛼 1, 𝛽𝛽 3, 𝛾𝛾2L peptides in whole cell

lysates 48 h post-transfection by western blotting (Figure 4.3). We hypothesized the

protein expression levels for the 𝛼𝛼1:𝛽𝛽 3:𝛾𝛾2L subunits would align with the canonical 2:2:1

subunit composition ratio, an established observation made for heterologous expression of
synaptic GABAA receptors (Angelotti et al., 1993; Baumann et al., 2003; Jacob et al.,
2008). However, a ratio closer to 5:5:1 of 𝛼𝛼1:𝛽𝛽 3:𝛾𝛾2L was observed (15 µg total protein,

Figure 4.3). The lower 𝛾𝛾2L protein expression levels, compared with the 𝛼𝛼1:𝛽𝛽 3 subunits,
could suggest a lower transfection or transcription/translation efficiency for the 𝛾𝛾2L subunit,
something previously noted by others (Botzolakis et al., 2016; Hinkle & Macdonald, 2003)
and remedied by attaching the 5’ end of an 11-residue flexible linker to 𝛾𝛾 2L’s carboxy

terminus with the linker’s 3’ end connected to a 1D4 epitope tag (Dostalova et al., 2014).
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The potency and efficacy of GABA, CZP, and VA were measured for the transient
and stably expressing GABAA receptor cell lines using the FMP Red Dye assay (Table
4.2). With the HEK293 cell line transiently expressing the GABA receptor, we observed a
40-fold decrease in GABA potency, but nearly a 50% increase in efficacy (maximum
stimulation) compared to the HEK293 cell harboring and expressing stably integrated
GABAA receptor subunit genes (808 nM vs. 19.6 nM; 13,309 AFUs vs. 9998 AFUs,
respectively). This might suggest a differential expression profile of GABAA receptor
isoforms lacking one or both of GABA’s orthosteric binding sites, but capable of forming
functional ligand-gated ion channels at the cell’s surface (the 𝛽𝛽 3, the 𝛼𝛼1:𝛽𝛽 3, or the 𝛼𝛼1:𝛽𝛽 3:𝛾𝛾2L
subunits) (Botzolakis et al., 2016; Masiulis et al., 2019; Miller & Aricescu, 2014; Yip et

al., 2013). This hypothesis awaits additional experimental evidence in the form of protein
expression analysis of the plasma membrane fraction.
Both the transient and stable cell lines expressing the GABAA receptor genes
displayed BZD sensitivity as evident by CZP concentration-dependent observations
(Figure 4.4), thus affirming successful incorporation of the 𝛾𝛾2L subunit into the GABAA

receptor pseudopentameric structure because the BZD binding site resides on the
extracellular domain of the 𝛼𝛼 – 𝛾𝛾 interface (Han et al., 2019; Masiulis et al., 2019). CZP’s

potency, determined in the absence of GABA, was slightly lower in the HEK293 cell line
transiently expressing the GABAA receptor genes, though not statistically significant in

comparison to the HEK293 cell line stably expressing the GABAA receptor genes
(EC50:15.6nM vs. 8.2nM, respectively) (Table 4.2). The efficacy, however, was almost
30% lower in the transient expressing cells compared to the stably expressing HEK293 cell
line (3880AFU vs. 5332AFU, respectively; p < 0.05). As alluded to previously, the FMP
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Red Dye (and quite possibly the masking dye) partially agonizes the GABAA receptor,
therefore lowering the maximal threshold for desenzitation.
We were not able to confirm the widely reported positive modulatory activity of CZP
on GABA sensitivity using the FMP Red Dye. In numerous attempts, we were not able to
reproducibly document an enhanced CZP dose response at suboptimal concentrations of
GABA (from 5 to 30 % of the GABA concentration necessary for maximal efficacy
measurements). Nonetheless, a reliable and reproducible dose dependent CZP potentiation
response in both cells transiently and stably expressing the GABA receptor subunit genes
was documented (Figure 4.4). The results appear to confirm the presence of an accessible
BZD binding site, which would be necessary for validating the exact binding site on the
GABAA receptor of novel chemistries with PAM activity.
Furthermore, we also confirmed the presence of at least one VA binding site within
both our transient and stable HEK293 cell lines. Once VA’s concentration-dependent
responses were plotted on a log(concentration)-response graph (Figure 4.4, A & D), VA’s
potency and efficacy for the human GABAA receptor transiently and stably expressed in
HEK293 cells using the FMP Red Dye assay without the presence of GABA could be
calculated (Potency: 2502nM (Transient) vs. 3687nM (Stable); Efficacy 5,935AFUs
(Transient) vs. 5,255AFUs (Stable)) (Table 4.2).
We were unable to confirm the seminal work of Hering et al. (Khom et al., 2007) and
Mohler et al. (Benke et al., 2009) establishing VA’s primary mechanism of actions as a
positive allosteric modulator of GABAA receptor PAM. As already noted elsewhere, we
suspect this is because the FMP Red Dye itself can induce a partial potentiation of the
GABAA receptor via the barbiturate binding site (Mennerick et al., 2010; Nik et al., 2017),
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thus short-circuiting the potential to observe the action of other PAM molecules.
Regardless, the FMP Red Dye assay was sufficient to document potentiation of the GABAA
receptor by VA, encouraging further screening of VA constrained analogs and other novel
chemistries for their level of direct potentiation of the human GABAA (𝛼𝛼1, 𝛽𝛽 3, 𝛾𝛾2L) receptor

genes expressed transiently and in stably transformed HEK293 cells.
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Table 4.2 GABA, CZP, & VA potency (nM) and efficacy (AFUs) of transiently vs. stably
expressed human GABAA receptors in HEK293 cells
Treatment
GABA

Potencya
Transient
Stable
808 ± 206
19.6 ± 6.1*

Efficacyb
Transient
Stable
13309 ± 953 9998 ± 430

Hill Slopec
Transient Stable
0.8 ± 0.1 1.3 ± 0.4

CZP

15.6 ± 5.5

8.2 ± 1.1

3880 ± 72

5332 ± 17*

1.4 ± 0.6 1.9 ± 0.6

VA

2502 ± 278

3687 ± 901

5935 ± 104

5255 ± 495

2.3 ± 0.5 2.5 ± 1.3

ABA

not active

not tested

CPol

not active

not tested

GA3

not active

not tested

Potency values are in nM ± SEM; bEfficacy values are AFUs ± SEM; cslope ± SEM; Means of transient and stable cell lines were
compared using the Student’s t-test (unpaired), *p < 0.05.
a
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4.3.3 The sesquiterpenoids ABA & CPol along with diterpenoid GA3 showed no
detectable level of potentiation for transiently expressed human GABAA (𝛼𝛼1, 𝛽𝛽 3,
𝛾𝛾2L) receptors

Although unsuccessful in efforts to create biosynthetically constrained, rigid analogs

of VLD (CHAPTER 2) oxidized to their carboxylic acid form (CHAPTER 3), we were
able to screen and evaluate three decorated terpenoids with varying degrees of structural
rigidity (Figure 4.1, Structures D-F) in our FMP Red Dye assay. Abscisic acid (ABA)
(Figure 4.1, Structure D) is a 15-carbon breakdown product from the carotenoid
zeaxanthin, and contains one oxygenated (ketone and tertiary alcohol) with a sixmembered ring connected to a flexible, isopentyl side chain successively oxidized at the
terminal methyl substituent (Finkelstein & Rock, 2002; Izquierdo-Bueno et al., 2018). To
date, ABA’s biological role as a plant growth regulator, controlling stomatal closure,
cuticular wax accumulation, leaf senescence, bud dormancy, seed germination, osmotic
regulation, and growth inhibition is well documented (Chen et al., 2020). Cyclopartheniol
(CPol) (Figure 4.1, Structure E) is a C15 sesquiterpenoid first extracted from the
defoliated twigs of Parthenium argentatum (Crevoisier et al., 1984) closely resembling
allo-aromadendrene’s

structure

2.1,

(Figure

Structure

#10).

CPol’s

gem-

dimethylcycopropyl unit was hypothesized to contribute to the biosynthetic origins of
many

aristoloane’s,

including

aromadendrane’s,

secoaromadendrane’s,

cycloaromadendrane’s , and lepidozane’s and documented for their anti-viral,
antimicrobial, and antifeedant activities (Durán-Peña et al., 2015). Gibberellic acid (GA3)
(Figure 4.1, Structure F) is a pentacyclic oxygenated diterpenoid which functions as plant
phytohormone involved in cell growth processes such as, stem elongation (Nagai et al.,
2020)). Unfortunately, no concentration dependent GABAA potentiation responses in the
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FMP RED dye assay were observed up to 10,000 nM for ABA, CPol, or GA3 (Figure 4.6,
Graph A). Thus, we concluded these molecules lack an ability to either bind to or modulate
the GABAA receptor (Table 4.2). It is also conceivable the differences in the water
solubility of ABA (3.2 g/L), CPol (≈0.012 g/ L) 4, and GA3 (5 g/L) may have negatively
influenced any potential GABAA receptor- ligand binding interactions. In either scenario,
the FMP Red Dye assay independently identified CZP and VA as “active” GABA receptor
chemistries – previously well-characterized positive allosteric GABAA receptor allosteric
modulators by several other groups (Benke et al., 2009; Khom et al., 2007; Louiset et al.,
2000).
This is the first report, to our knowledge, of ABA, CPol, and GA3 evaluated for their
potential allosteric modulation of the human GABAA (𝛼𝛼1, 𝛽𝛽 3, 𝛾𝛾2L) receptors. Though ABA,
CPol, nor GA3 displayed detectable levels of activity (up to the 10,000nM 5), they did help
strengthen the specificity within our cell-based fluorescence biological assay to, without
bias, correctly identify known biologically active chemistries, while eliminating “inactive”
compounds.

4

This is the estimated water solubility of a spathulenol (a tri-cyclic monooxygenated sesquiterpene with a
gem-dimethyl ring structure) reported by the Good Scents Company
5 Final in-well concentration was limited by the compound’s solubility (in DMSO) and the maximum
DMSO percentage tolerated by the HEK293 cells (0.05%)
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4.3.4

Varying the 𝛼𝛼 1, 𝛽𝛽 3, & 𝛾𝛾2L subunits’ availability directly impacts GABA’s, CZP’s,
&VA’s potency and efficacy for transiently expressed GABAA receptor in naive
HEK293 cells
In a last set of experiments, we envisioned having a malleable, recombinant GABAA

receptor transient expression system to further investigate the subunit specific binding sites
of those chemistries screened and found to have a modulatory activity above the vehicle
control using the FMP Red Dye assay. As noted by the MacDonald research group and
others (Angelotti et al., 1993; Botzolakis et al., 2016; Schofield et al., 1987; Tretter et al.,
1997), varying the DNA concentration for the genes encoding for the 𝛼𝛼(1-6), 𝛽𝛽(1-3), and

𝛾𝛾(1-3) subunits (the mature peptide expression ratio for GABAA receptor subunit subtypes

commonly found within the central nervous system (Olsen & Sieghart, 2009)) should
translate to directly influencing the subunit stoichiometry of the multimeric GABAA
receptor, directly impacting the receptor’s channel kinetics, neuropharmacology, and
subcellular localization.
We therefore varied the transfected DNA concentrations from 1:1:1 to 2:2:1 and
1:1:10 for the 𝛼𝛼 1, 𝛽𝛽 3, and 𝛾𝛾2L subunits and noted the impacts to the GABA, CZP and VA

GABAA receptor pharmacology (Table 4.3, Figure 4.6). Transfection of the 𝛾𝛾2L plasmid
DNA at 50% of the individual 𝛼𝛼1 & 𝛽𝛽 3 subunit plasmid DNA amounts (2.9 µg vs. 5.8 µg),

increased GABA’s potency 2-fold (though not statistically significant), with a concomitant

decrease of 1.5 times (p < 0.001) to the maximum channel stimulation (efficacy) in
reference to the transfection ratio (T.R.) of 1:1:1 (260nM vs. 808nM; 8284 AFUs vs.
13,309 AFUs, respectively). Conversely, when cells were transfected with 12µg of the 𝛾𝛾2L
plasmid DNA and 1.25 µg for each of the 𝛼𝛼1 & 𝛽𝛽 3 subunits (T.R. 1:1:10), we observed a
2.5-fold decrease in potency and a 1.2 time in increase in efficacy (P < 0.003), compared
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to the T.R. of 1:1:1 (2033nM vs. 808nM; 15,730 AFUs vs. 13,309 AFUs, respectively).
Altogether, these results suggest that transfecting in the 𝛼𝛼1, 𝛽𝛽 3, & 𝛾𝛾2L subunits at a 2:2:1

ratio may reduce alternative GABAA confirmations and support the canonical 𝛽𝛽 – 𝛼𝛼 – 𝛽𝛽 𝛼𝛼 - 𝛾𝛾 subunit GABAA receptor formation.

Interestingly, we observed little to no change in CZP’s potency and efficacy across

the 1:1:1, 2:2:1, and 1:1:10 transient cell lines (Table 4.3, Figure 4.6). This would suggest
the canonical BZD binding site was preserved and functioning properly, regardless of the
𝛾𝛾2L subunit availability. Finally, in the 2:2:1 and 1:1:10 cell lines, we observed a significant
increase in VA’s potency, which was indetermined given the concentration-dependent
response curves kept rising and never plateaued at 10,000nM (the maximum tested
concentration). VA efficacies for 2:2:1 and 1:1:10 transfected cells slightly decreased (P <
0.003) or nearly doubled (P < 0.003) compared with the T.R. 1:1:1 cell line (3982 AFUs
vs. 9048 AFUs vs. 5935 AFUs, respectively). Therefore, increasing the transfection 𝛽𝛽 3

subunit concentration by 50% or decreasing it approximately 8-fold with respect to the
𝛾𝛾2L, has bifurcating effects on VA’s efficacy, while shifting VA’s potency further right on
the concentration-response curve. Taken together, additional transfection permutations,
such as strictly only transfection of the 𝛽𝛽 3 subunit and 𝛼𝛼1+ 𝛽𝛽 3 subunits are warranted to

grasp a more comprehensive understanding of the impact on GABAA receptor’s
pharmacology to provide the necessary benchmarks for comparing the novel chemistries
across a diverse recombinantly expressed GABAA receptor subunit conformers.
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Table 4.3 Potency and efficacy of GABA, CZP, & VA for transiently expressed human
GABAA receptors with varying 𝛼𝛼1, 𝛽𝛽 3, & 𝛾𝛾2L subunit availability
T.R.
1:1:1

GABA
Potency
Efficacyc
808 ± 206
13309 ± 953

2:2:1

260 ± 76

8284 ± 243***

1:1:10

2033 ± 431

15730 ± 947**

a

b

CZP

Potency
16 ± 6

VA

Efficacy
3880 ± 72

Potency
2502 ± 278

Efficacyc
5935 ± 104

12

2588 ± 375*

>10,000d

3982 ± 72**

23 ± 3

3960 ± 84

>10,000d

9048**

b

c

b

T.R, transfection DNA ratio of expression vectors harboring the 𝛼𝛼1, 𝛽𝛽3, & 𝛾𝛾2L GABAA receptor subunit coding DNA, respectively;
Potency values are nM ± SEM; cEfficacy values are AFUs ± SEM; dAccurate statistical difference not definable given sample size was
n=2; Comparison of individual means for 1:1:1 to 2:2:1 and 1:1:10 cell lines by Fishers Least Significant Difference test (uncorrected),
*p < 0.05, **p< 0.003, ***p< 0.001.
a
b
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Figure 4.6 GABA (A), VA (B), and CZP (C) for HEK293 concentration-dependent
response curves for naïve HEK293 cells transfected at (▪) 1:1:1, (●) 2:2:1, (△) 1:1:10 with
the α1, β3, γ2L the human GABAA receptor subunits, respectively. (A) HEK293 cells
transfected at 2:2:1 exhibited two-to-seven-fold greater GABA potencies, than cells
transfected at 1:1:1 and 1:1:10. VEH; vehicle control (red filled in shapes) (B) The 1:1:1
HEK293 transfected cells demonstrated the typical concentration-dependent response,
reaching saturation prior to 10,000nM of VA, the maximum tested dose. Potencies and
efficacies were unable to be calculated for the 2:2:1 and 1:1:10 transfected cells, given that
a saturation response was not observed. (C) All three transfected HEK293 cells
demonstrated relatively the same level of potency and efficacy for CZP. This would
indicate both the alpha and gamma subunits were correctly assembled in the ER and
trafficked to the cell surface for functional expression of the benzodiazepine binding site
(Dostalova et al., 2014; Masiulis et al., 2019).
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4.4

Conclusions
In conclusion, this work establishes a cell-based fluorescence bioassay for the

detection of novel direct activators of the human GABAA (α1, β3, γ2L) receptor in both
transiently and stably expressed. Albeit, the DiSBAC1(3) dye may have a partial agonistic
effect on the recombinantly expressed human GABAA (α1, β3, γ2L) receptors, the FMP
Red Dye assay provides a facile, sensitive tool to indirectly measure and quantify specific
binding interaction at the GABAA receptor. Thus, allowing for additional ways to conduct
drug discovery structure-activity relationship studies. It is not the goal for the such tools to
replace the gold-standard patch-clamp electrophysiology techniques, but merely provide a
method for pre-screening through a large chemical library for reduction in the more labor
intensive and costly patch-clamp type of experimentation.
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CHAPTER 5. CONCLUSIONS AND PERSPECTIVES
5.1

Conclusions and perspectives
The intent of this dissertation was to develop a biosynthetic platform for the

generation of structural analogs that could be tested in a facile bioassay for their
potentiation of the GABAA receptor. Though the full embodiment of this vision might not
have been realized, the construction of a platform to evaluate microbially synthesized VA
analogs from engineered VDS mutant enzymes in a “plug-in-play” type manner was
developed. One of the next steps that should be undertaken is the development of a greater
diverse VDS mutant library with an enhanced high-throughput chemical screening analysis
(O'Maille et al., 2008). In parallel, an engineered ZXB yeast line, or possibly another high
terpene yielding yeast host, should be genetically engineered to contain with multiple
copies of the GAO and its P450 reductase at various and previously uncharacterized
genomic loci near ARS sites to improve the yield of biosynthetically oxidized
sesquiterpenes. These efforts would afford a stream-lined and more productive route for
obtaining the necessary VDS mutant enzymes, which then could be expressed in a yeast
host extrachromosomally or chromosomally inserted, yielding higher conversation
efficiencies of structurally constrained VLD analogs to their final carboxylated forms at
titers of 10-20mg/L. Once purified (purity >90%), by preparative TLC or HPLC, the
structurally constrained analogs can immediately into the FMP Red Dye assay for
screening in both the stably and transiently (1:1:1) expressing human GABAA (α1, β3, γ2L)
receptor cell lines for preliminary pharmacological characterization. Analogs which
demonstrate at least the same level of potentiation to VA, should then be rescreened in a

transiently expressing human GABAA (β3 only) receptor cell line for probing its putative
receptor binding site, which may or may not be the same as VA (TM2 domain on the β2,3).
If the compound(s) show greater than 2-fold better potency to VA and equivalent or greater
efficacy, they could be targeted as “ready to test by patch-clamping.” At which time, it
would be necessary to seek out additional support to setup the patch-clamping studies,
while continuing to screen structural conformers of VA for enhance potencies and
efficacies for allosteric modulation of the human GABAA (α1, β3, γ2L) receptor.
Furthermore, adopting additional GABAA receptor subunit subtypes into the transient
expression system, would significantly improve one’s ability to uncover potentiation
selectivity for GABAA receptor specific subunit subtype. Ultimately aiding to focusing on
generating potentially novel anxiolytic chemistries that would have reduced adverse effects
and low abuse potential of the currently FDA-approved anti-anxiety treatments.
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